Protein tyrosine phosphatase inhibitor and application thereof

By developing PTPN1/PTPN2 inhibitor compounds to combine with immunotherapeutic agents, the problems of incomplete response and resistance in cancer immunotherapy have been solved, thus enhancing the efficacy of cancer treatment.

CN118922412APending Publication Date: 2024-11-08NERIO THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030108.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-02
Filing Date
2023-02-01
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing cancer immunotherapies, such as checkpoint blockade therapy, suffer from incomplete clinical responses and inherent or acquired resistance, limiting treatment efficacy in patient populations. Furthermore, protein tyrosine phosphatases PTPN2 and PTPN1 play crucial roles in signal transduction, impacting treatment outcomes.

Method used

A compound of formula (I) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof has been developed as a PTPN1/PTPN2 inhibitor to enhance IFNγ sensing and signal transduction, enhance the efficacy of cancer immunotherapy, and be used in combination with immunotherapeutic agents such as anti-PD-1 antibodies, anti-PD-L1 antibodies or anti-CTLA-4 antibodies for treatment.

Benefits of technology

By inhibiting PTPN1/PTPN2, the efficacy of immunotherapy can be enhanced, increasing sensitivity to cancer, improving incomplete response and resistance issues, and enhancing treatment effects when combined with other immunotherapeutic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005057820540000021
    Figure BDA0005057820540000021
  • Figure BDA0005057820540000161
    Figure BDA0005057820540000161
  • Figure BDA0005057820540000233
    Figure BDA0005057820540000233
Patent Text Reader

Abstract

Provided herein are compounds, compositions and methods useful for inhibiting protein tyrosine phosphatase, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions, such as cancer or metabolic diseases, that are advantageously responsive to treatment with PTPN1 or a PTPN2 inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 63 / 305,789, filed on February 2, 2022, which is incorporated herein by reference in its entirety. Background of the Invention

[0004] Cancer immunotherapy regimens targeting immune evasion mechanisms, including checkpoint blockade (e.g., PD-1 / PD-L1 and CTLA-4 blocking antibodies), have proven effective in treating a variety of cancers, significantly improving outcomes in some populations that are difficult to treat with conventional therapies. However, incomplete clinical responses and the development of intrinsic or acquired resistance continue to limit the patient population that may benefit from checkpoint blockade.

[0005] Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T-cell protein tyrosine phosphatase (TC-PTP), is an intracellular member of subfamily 1 of phospho-tyrosine-specific phosphatases that control multiple cellular regulatory processes by removing phosphate groups from tyrosine substrates. PTPN2 is ubiquitously expressed, but expression is highest in hematopoietic and placental cells. In humans, PTPN2 expression is post-transcriptionally controlled by the presence of two splice variants: a 45 kDa form that contains a nuclear localization signal C-terminally upstream of the splice junction; and a 48 kDa canonical form that has a C-terminal ER retention motif. The 45 kDa isoform can be passively infused into the cytosol under certain conditions of cellular stress. Both isoforms share an N-terminal phospho-tyrosine phosphatase catalytic domain. PTPN2 negatively regulates signaling of non-receptor tyrosine kinases (e.g., JAK1, JAK3), receptor tyrosine kinases (e.g., INSR, EGFR, CSF1R, PDGFR), transcription factors (e.g., STAT1, STAT3, STAT5a / b), and Src family kinases (e.g., Fyn, Lck). As a key negative regulator of the JAK-STAT pathway, PTPN2 is used to directly regulate signaling via cytokine receptors, including IFNγ. The PTPN2 catalytic domain shares 74% sequence homology with PTPN1 (also known as PTP1B) and shares similar enzymatic kinetics. Data from an in vivo loss-of-function genetic screen using CRISPR / Cas9 genome editing in a mouse B16F10 transplantable tumor model showed that loss of the Ptpn2 gene in tumor cells improved the response to an immunotherapy regimen of GM-CSF secreting vaccine (GVAX) plus PD-1 checkpoint blockade. Loss of PTPN2 sensitizes tumors to immunotherapy by enhancing IFNγ-mediated effects on antigen presentation and growth inhibition. The same screen also revealed that genes known to be involved in immune evasion, including PD-L1 and CD47, were also depleted under immunotherapy selective pressure, while genes involved in the IFNγ signaling pathway, including IFNGR, JAK1, and STAT1, were enriched. These observations point to a putative role for therapeutic strategies that enhance IFNγ sensing and signaling in enhancing the efficacy of cancer immunotherapy regimens.

[0006] Protein tyrosine phosphatase non-receptor type 1 (PTPN1), also known as protein tyrosine phosphatase 1B (PTP1B), has been shown to play a key role in insulin and leptin signaling and is the primary mechanism for downregulating insulin and leptin receptor signaling pathways. Animals lacking PTP1B have improved glucose regulation and lipid profiles and are resistant to weight gain when treated with a high-fat diet. Therefore, PTP1B inhibitors are expected to be useful in the treatment of type 2 diabetes, obesity, and metabolic syndrome. Summary of the invention

[0007] Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:

[0008]

[0009] in:

[0010] Ring A is a 7- to 15-membered cycloalkyl group or a 7- to 15-membered heterocycloalkyl group containing 1 to 4 heteroatoms selected from O, S and N;

[0011] Each R 1 independently deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally replaced by one or more R 1a replace;

[0012] or two R on the same atom 1 Together they form an oxo group;

[0013] Each R 1a independently deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0014] or two R on the same atom 1a Together they form an oxo group;

[0015] n is 0 to 6;

[0016] X is CR X or N;

[0017] R X For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0018] Y is CR Y or N;

[0019] R Y For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0020] Z is CR Z or N;

[0021] R Z For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0022] W is CR W or N;

[0023] R W For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c Rd 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0024] Each R a Independently for C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkyl (cycloalkyl), C 1 -C 6 Alkyl (heterocycloalkyl), C 1 -C 6 Alkyl (aryl) or C 1 -C 6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0025] Each R b are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkyl (cycloalkyl), C 1 -C 6 Alkyl (heterocycloalkyl), C 1 -C 6 Alkyl (aryl) or C 1 -C 6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0026] Each R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkyl (cycloalkyl), C 1 -C 6 Alkyl (heterocycloalkyl), C 1 -C 6 Alkyl (aryl) or C 1 -C 6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0027] or R c and Rd, together with the atoms to which they are attached, form heterocycloalkyl optionally substituted with one or more R; and

[0028] Each R is independently deuterium, halogen, -CN, -OH, -OC 1 -C 6 Alkyl, -S(=O)C 1 -C 6 Alkyl, -S(=O) 2 C 1 -C 6 Alkyl, -S(=O) 2 NH 2 、-S(=O) 2 NHC 1 -C 6 Alkyl, -S(=O) 2 N(C 1 -C 6 alkyl) 2 、-NH 2 、-NHC 1 -C 6 Alkyl, -N(C 1 -C 6 alkyl) 2 、-NHC(=O)OC 1 -C 6 Alkyl, -C(=O)C 1 -C 6 Alkyl, -C(=O)OH, -C(=O)OC 1 -C 6 Alkyl, -C(=O)NH 2 、-C(=O)N(C 1 -C 6 alkyl) 2 、-C(=O)NHC 1 -C 6 Alkyl, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C 6 heteroalkyl;

[0029] Or two R on the same atom together form an oxo group.

[0030] Also disclosed herein is a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and a pharmaceutically acceptable excipient.

[0031] Also disclosed herein is a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0032] Also disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition disclosed herein.

[0033] In some embodiments, the method further comprises administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[0034] Also disclosed herein is a method of treating type 2 diabetes in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0035] Also disclosed herein is a method of treating type 2 diabetes in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition disclosed herein.

[0036] Also disclosed herein is a method of treating and / or managing obesity in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0037] Also disclosed herein is a method of treating and / or managing obesity in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition disclosed herein.

[0038] Also disclosed herein is a method of treating a metabolic disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0039] Also disclosed herein is a method of treating a metabolic disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition disclosed herein.

[0040] Incorporation by reference

[0041] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION

[0042] definition

[0043] In the following description, certain specific details are set forth in order to provide a thorough understanding of the various embodiments. However, it will be understood by those skilled in the art that the invention may be practiced without these details. In other cases, well-known structures are not shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context requires otherwise, in this specification and the claims that follow, the word "comprise" and its variations (such as "comprises" and "comprising") shall be deemed to have an open inclusive meaning, that is, to be deemed to be "including, but not limited to". In addition, the headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.

[0044] References in this specification to "some embodiments" or "an embodiment" mean that the characteristic features, structures, or characteristics described in conjunction with the embodiments are included in at least one embodiment. Therefore, the phrases "in one embodiment" or "in an embodiment" appearing in various places throughout this specification do not necessarily all refer to the same embodiment. In addition, the specific features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. In addition, unless the context clearly dictates otherwise, as used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents. It should also be noted that the term "or" is generally used in its sense that includes "and / or" unless the context clearly dictates otherwise.

[0045] Unless otherwise indicated, the following terms as used herein have the following meanings:

[0046] "Oxo" refers to =0.

[0047] "Carboxyl" refers to -COOH.

[0048] "Cyano" refers to -CN.

[0049] "Alkyl" refers to a straight or branched saturated hydrocarbon monovalent group having one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl and hexyl, as well as longer alkyl groups such as heptyl, octyl and the like. Whenever it appears in this document, 1 -C 6 Alkyl" or "C 1-6 The numerical range of "alkyl" means that the alkyl group can be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also encompasses the presence of the term "alkyl" where no numerical range is specified. In some embodiments, the alkyl group is C 1-10 In some embodiments, the alkyl group is C 1-6 In some embodiments, the alkyl group is C 1-5 In some embodiments, the alkyl group is C 1-4 In some embodiments, the alkyl group is C 1-3 Alkyl. Unless otherwise specifically stated in the specification, the alkyl group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl group may be optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the alkyl group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl group is optionally substituted with halogen.

[0050] "Alkenyl" refers to a straight or branched hydrocarbon monovalent group having one or more carbon-carbon double bonds and having two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in a cis or trans configuration about the double bond and is understood to include both isomers. Examples include, but are not limited to, vinyl (-CH=CH 2 ), 1-propenyl (-CH 2 CH=CH 2 ), isopropenyl [-C(CH 3 )=CH2 ], butenyl, 1,3-butadienyl and the like. Whenever it appears in this document, a 2 -C 6 "Alkenyl" or "C 2-6 The numerical range of "alkenyl" means that the alkenyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, but the present definition also covers the existence of the term "alkenyl" in which no numerical range is specified. Unless otherwise specifically stated in the present specification, the alkenyl group can be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the alkenyl group is optionally substituted by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the alkenyl group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl group is optionally substituted with halogen.

[0051] "Alkynyl" refers to a straight or branched hydrocarbon monovalent group having one or more carbon-carbon triple bonds and having two to about ten carbon atoms, more preferably two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, and the like. Whenever it appears herein, a substituted alkynyl group such as "C 2 -C 6 Alkynyl" or "C 2-6 The numerical range of "alkynyl" means that the alkynyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, but the present definition also covers the existence of the term "alkynyl" in which no numerical range is specified. Unless otherwise specifically stated in the present specification, the alkynyl group can be optionally substituted by, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the alkynyl group is optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the alkynyl group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkynyl group is optionally substituted with halogen.

[0052] "Alkylene" refers to a straight or branched divalent hydrocarbon chain. Unless otherwise specifically stated in the specification, alkylene can be optionally substituted by, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, alkylene can be optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the alkylene group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene group is optionally substituted with halogen.

[0053] "Alkoxy" refers to a group of the formula -OR a A group in which R a is alkyl as defined. Unless otherwise specifically stated in the specification, alkoxy groups may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, alkoxy groups are optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the alkoxy group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy group is optionally substituted with halogen.

[0054] "Aryl" refers to a radical derived from a hydrocarbon ring system containing 6 to 30 carbon atoms and at least one aromatic ring. The aryl group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused to a cycloalkyl or heterocycloalkyl ring, the aryl is bonded via an aromatic ring atom) or bridged ring system. In some embodiments, the aryl group is a 6- to 10-membered aryl group. In some embodiments, the aryl group is a 6-membered aryl (phenyl). Aryl groups include, but are not limited to, aryl groups derived from the following hydrocarbon ring systems: anthracene, naphthylene, phenanthrenyl, anthracene, azulene, benzene, Fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenanthene, phenanthrene, pleiadene, pyrene and benzo[9,10]phenanthrene. Unless otherwise specifically stated in the specification, aryl can be optionally substituted, for example, by halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, aryl is optionally substituted by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH2 or-NO 2 In some embodiments, the aryl group is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 In some embodiments, the aryl group is optionally substituted with halogen.

[0055] "Cycloalkyl" refers to a partially or fully saturated monocyclic or polycyclic carbocyclic ring, which may include fused (when fused to an aryl or heteroaryl ring, the cycloalkyl is bonded via a non-aromatic ring atom) or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having: three to fifteen carbon atoms (C 3 -C 15 Cycloalkyl or C 3 -C 15 cycloalkenyl), three to ten carbon atoms (C 3 -C 10 Cycloalkyl or C 3 -C 10 Cycloalkenyl), three to eight carbon atoms (C 3 -C 8 Cycloalkyl or C 3 -C 8 Cycloalkenyl), three to six carbon atoms (C 3 -C 6 Cycloalkyl or C 3 -C 6 Cycloalkenyl), three to five carbon atoms (C 3 -C 5 Cycloalkyl or C 3 -C 5 Cycloalkenyl) or three to four carbon atoms (C 3 -C 4 Cycloalkyl or C 3 -C 4In some embodiments, the cycloalkyl is a 3- to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane and bicyclo[3.3.2]decane and 7,7-dimethyl-bicyclo[2.2.1]heptyl. Partially saturated cycloalkyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Unless otherwise specifically stated in the specification, cycloalkyls are optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the cycloalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the cycloalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 In some embodiments, the cycloalkyl is optionally substituted with halogen.

[0056] "Halo" or "halogen" refers to bromine, chlorine, fluorine, or iodine. In some embodiments, halogen is fluorine or chlorine. In some embodiments, halogen is fluorine.

[0057] "Haloalkyl" refers to an alkyl group as defined above substituted with one or more halo groups as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl and the like.

[0058] "Hydroxyalkyl" refers to an alkyl group as defined above that is substituted with one or more hydroxyl groups. In some embodiments, the alkyl group is substituted with one hydroxyl group. In some embodiments, the alkyl group is substituted with one, two, or three hydroxyl groups. Hydroxyalkyl groups include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl group is hydroxymethyl.

[0059] "Aminoalkyl" refers to an alkyl group as defined above that is substituted with one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyl includes, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.

[0060] "Deuterated alkyl" refers to an alkyl group as defined above that is substituted with one or more deuteriums. In some embodiments, the alkyl is substituted with one deuterium. In some embodiments, the alkyl is substituted with one, two, or three deuteriums. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six deuteriums. Deuterated alkyl includes, for example, CD 3 , CH 2 D. CHD 2 , CH 2 CD 3 , CD 2 CD 3 , CHDCD 3 , CH 2 CH 2 D or CH 2 CHD 2 In some embodiments, the deuterated alkyl group is CD 3 .

[0061] "Heteroalkyl" refers to an alkyl group in which one or more of the backbone atoms of the alkyl group is selected from atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof. The heteroalkyl group is attached to the remainder of the molecule at a carbon atom of the heteroalkyl group. In one aspect, the heteroalkyl group is C 1 -C 6 Heteroalkyl, wherein the heteroalkyl group comprises 1 to 6 carbon atoms and one or more atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof, wherein the heteroalkyl group is attached to the remainder of the molecule at a carbon atom of the heteroalkyl group. Examples of such heteroalkyl groups are, for example, -CH 2 OCH 3 、-CH 2 CH 2 OCH 3 、-CH 2 CH 2 OCH 2 CH 2 OCH 3 、-CH(CH 3 )OCH 3 、-CH 2 NHCH 3 、-CH 2 N(CH3 ) 2 、-CH 2 CH 2 NHCH 3 or -CH 2 CH 2 N(CH 3 ) 2 Unless otherwise specifically stated in the specification, heteroalkyl is optionally substituted by, for example, oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, heteroalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF 3 , -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the heteroalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 In some embodiments, the heteroalkyl group is optionally substituted with halogen.

[0062] "Heterocycloalkyl" refers to a 3- to 24-membered partially or fully saturated ring group containing 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur. In some embodiments, heterocycloalkyl is fully saturated. In some embodiments, heterocycloalkyl contains one to three heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, heterocycloalkyl contains one to three heteroatoms selected from nitrogen and oxygen. In some embodiments, heterocycloalkyl contains one to three nitrogen. In some embodiments, heterocycloalkyl contains one or two nitrogen. In some embodiments, heterocycloalkyl contains one nitrogen. In some embodiments, heterocycloalkyl contains one nitrogen and one oxygen. Unless otherwise specifically stated in this specification, heterocycloalkyl may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused with an aryl or heteroaromatic ring, the heterocycloalkyl is bonded via a non-aromatic ring atom) or bridged ring system; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. Representative heterocycloalkyl groups include, but are not limited to, heterocycloalkyl groups having two to fifteen carbon atoms (C 2 -C 15 Heterocycloalkyl or C 2 -C 15 Heterocycloalkenyl), two to ten carbon atoms (C 2 -C 10 Heterocycloalkyl or C 2 -C 10 Heterocycloalkenyl), two to eight carbon atoms (C 2 -C 8 Heterocycloalkyl or C 2 -C8 Heterocycloalkenyl), two to seven carbon atoms (C 2 -C 7 Heterocycloalkyl or C 2 -C 7 Heterocycloalkenyl), two to six carbon atoms (C 2 -C 6 Heterocycloalkyl or C 2 -C 6 Heterocycloalkenyl), two to five carbon atoms (C 2 -C 5 Heterocycloalkyl or C 2 -C 5 Heterocycloalkenyl) or two to four carbon atoms (C 2 -C 4 Heterocycloalkyl or C 2 -C 41,2-Dihydro-1,2-di ... The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Unless otherwise specified, heterocycloalkyl has 2 to 10 carbons in the ring. It should be understood that when referring to the number of carbon atoms in heterocycloalkyl, the number of carbon atoms in heterocycloalkyl is not the same as the total number (including heteroatoms) of atoms (i.e., the skeleton atoms of the heterocycloalkyl ring) constituting the heterocycloalkyl. In some embodiments, heterocycloalkyl is 3- to 8-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is 3- to 7-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is 3- to 6-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is 4- to 6-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is 5- to 6-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is 3- to 8-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is 3- to 7-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is 3- to 6-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is 4- to 6-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is 5- to 6-membered heterocycloalkenyl. Unless otherwise specifically stated in the specification, heterocycloalkyl can be optionally substituted as described below, for example, by oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, heterocycloalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the heterocycloalkyl group is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 In some embodiments, the heterocycloalkyl is optionally substituted with halogen.

[0063] "Heteroaryl" refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen. The heteroaryl may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused to a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded via an aromatic ring atom) or bridged ring system; and the nitrogen, carbon or sulfur atoms in the heteroaryl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, heteroaryl is a 6-membered heteroaryl. In some embodiments, heteroaryl is a 5-membered heteroaryl. Examples include, but are not limited to, aza benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranyl, thiophene, benzothienyl / benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnosinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, isoindolyl, indolyl, isoindolyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepine The heteroaryl group may be optionally substituted with, for example, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl and the like. In some embodiments, the heteroaryl group is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 or-NO 2 In some embodiments, the heteroaryl group is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 In some embodiments, the heteroaryl group is optionally substituted with halogen.

[0064] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where the event or circumstance does not occur. For example, "optionally substituted alkyl" means "alkyl" or "substituted alkyl" as defined above. In addition, an optionally substituted group may be unsubstituted (e.g., -CH 2 CH 3 ), completely replaced (e.g. -CF 2 CF 3 ), monosubstituted (e.g. -CH 2 CH 2 F) or any degree of substitution between fully substituted and monosubstituted (e.g., -CH 2 CHF 2 、-CH 2 CF 3 , -CF 2 CH 3 ,-CFHCHF 2With respect to any group containing one or more substituents, it will be understood by those skilled in the art that such groups are not intended to introduce any substitution or substitution pattern that is sterically impractical and / or synthetically infeasible (e.g., substituted alkyl includes optionally substituted cycloalkyl, which is in turn defined to include optionally substituted alkyl, potentially ad infinitum). Thus, any substituent described will generally be understood to have a maximum molecular weight of about 1,000 Daltons and more typically up to about 500 Daltons.

[0065] The term "one or more" means that the subject group is optionally substituted by one, two, three or four substituents when referring to optional substituents. In some embodiments, the subject group is optionally substituted by one, two or three substituents. In some embodiments, the subject group is optionally substituted by one or two substituents. In some embodiments, the subject group is optionally substituted by one substituent. In some embodiments, the subject group is optionally substituted by two substituents.

[0066] "Effective amount" or "therapeutically effective amount" refers to that amount of a compound administered to a mammalian subject, either in a single dose or as part of a series of doses, which is effective to produce the desired therapeutic effect.

[0067] "Treatment" of an individual (e.g., a mammal such as a human) or cell is any type of intervention used to attempt to alter the natural course of an individual or cell. In some embodiments, treatment includes administering a pharmaceutical composition after a pathological event has been initiated or contact with a pathogen, and includes stabilizing the condition (e.g., the condition does not worsen) or ameliorating the condition.

[0068] "Synergy" or "synergy" means that the effect of the combination is greater than the sum of the individual effects of the components at the same doses.

[0069] As used herein, the term "PTPN2-mediated" disorder or disease or alternatively "disease or disorder associated with PTPN2" means any disease or other deleterious condition in which PTPN2 or a mutant thereof is known to play a role. Thus, in some embodiments, the method relates to treating or lessening the severity of one or more diseases in which PTPN2 or a mutant thereof is known to play a role.

[0070] As used herein, the term "PTPN1-mediated" disorder or disease or alternatively "disease or disorder associated with PTPN1" means any disease or other deleterious condition in which PTPN1 or a mutant thereof is known to play a role. Thus, in some embodiments, the method relates to treating or lessening the severity of one or more diseases in which PTPN1 or a mutant thereof is known to play a role.

[0071] Compound

[0072] Described herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates or stereoisomers thereof, which are dual PTPN1 / PTPN2 inhibitors.

[0073] Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:

[0074]

[0075] in:

[0076] Ring A is a 7- to 15-membered cycloalkyl group or a 7- to 15-membered heterocycloalkyl group containing 1 to 4 heteroatoms selected from O, S and N;

[0077] Each R 1 independently deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C1 -C 6 Aminoalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally replaced by one or more R 1a replace;

[0078] or two R on the same atom 1 Together they form an oxo group;

[0079] Each R 1a independently deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0080] or two R on the same atom 1a Together they form an oxo group;

[0081] n is 0 to 6;

[0082] X is CR X or N;

[0083] R X For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0084] Y is CR Y or N;

[0085] R Y For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)Ra 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0086] Z is CR Z or N;

[0087] R Z For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0088] W is CR W or N;

[0089] R W For hydrogen, deuterium, halogen, -CN, -NO 2 、-OH、-OR a 、-S(=O)Ra 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0090] Each R a Independently for C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkyl (cycloalkyl), C 1 -C 6 Alkyl (heterocycloalkyl), C 1 -C 6 Alkyl (aryl) or C 1 -C 6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0091] Each R b are independently hydrogen, C1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkyl (cycloalkyl), C 1 -C 6 Alkyl (heterocycloalkyl), C 1 -C 6 Alkyl (aryl) or C 1 -C 6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0092] Each R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkyl (cycloalkyl), C 1 -C 6 Alkyl (heterocycloalkyl), C 1 -C 6 Alkyl (aryl) or C 1 -C 6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R;

[0093] or R c and R d together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; and

[0094] Each R is independently deuterium, halogen, -CN, -OH, -OC 1 -C 6 Alkyl, -S(=O)C 1 -C 6 Alkyl, -S(=O) 2 C 1 -C 6 Alkyl, -S(=O) 2 NH 2 、-S(=O) 2 NHC 1 -C 6 Alkyl, -S(=O) 2 N(C 1 -C 6 alkyl) 2 、-NH 2 、-NHC 1 -C 6 Alkyl, -N(C 1 -C 6 alkyl) 2 、-NHC(=O)OC 1 -C 6 Alkyl, -C(=O)C 1 -C 6 Alkyl, -C(=O)OH, -C(=O)OC 1 -C 6 Alkyl, -C(=O)NH 2 、-C(=O)N(C 1 -C 6 alkyl) 2 、-C(=O)NHC 1 -C 6 Alkyl, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C6 heteroalkyl;

[0095] Or two R on the same atom together form an oxo group.

[0096] In some embodiments of the compound of formula (I), ring A is a 7- to 10-membered cycloalkyl or 7- to 10-membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S and N. In some embodiments of the compound of formula (I), ring A is a 7- to 8-membered cycloalkyl or 7- to 8-membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S and N.

[0097] In some embodiments of compounds of formula (I), ring A is a 7- to 10-membered cycloalkyl. In some embodiments of compounds of formula (I), ring A is a 7- to 9-membered cycloalkyl. In some embodiments of compounds of formula (I), ring A is a 7- to 8-membered cycloalkyl. In some embodiments of compounds of formula (I), ring A is a 7-membered cycloalkyl. In some embodiments of compounds of formula (I), ring A is a 7- to 10-membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S, and N. In some embodiments of compounds of formula (I), ring A is a 7- to 8-membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S, and N. In some embodiments of compounds of formula (I), ring A is a 7-membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S, and N. In some embodiments of compounds of formula (I), the heterocycloalkyl in ring A contains 1 to 3 heteroatoms selected from O, S, and N. In some embodiments of the compounds of formula (I), the heterocycloalkyl group in ring A contains 1 to 3 heteroatoms selected from O and N. In some embodiments of the compounds of formula (I), the heterocycloalkyl group in ring A contains 1 or 2 heteroatoms selected from O and N. In some embodiments of the compounds of formula (I), the heterocycloalkyl group in ring A contains 1 heteroatom which is O. In some embodiments of the compounds of formula (I), the heterocycloalkyl group in ring A contains 1 heteroatom which is N.

[0098] In some embodiments of the compound of formula (I), X is N. In some embodiments of the compound of formula (I), X is CR X .

[0099] In some embodiments of the compound of Formula (I), R X Hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6In some embodiments of the compound of Formula (I), R X is hydrogen, deuterium, halogen or C 1 -C 6 In some embodiments of the compound of Formula (I), R X In some embodiments of the compound of formula (I), R X For fluorine.

[0100] In some embodiments of the compound of formula (I), Y is N. In some embodiments of the compound of formula (I), Y is CR Y .

[0101] In some embodiments of the compound of Formula (I), R Y Hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 In some embodiments of the compound of Formula (I), R Y For hydrogen, deuterium, halogen, -OH, -OR a or -NR c R d In some embodiments of the compound of formula (I), R Y It is -OH.

[0102] In some embodiments of the compound of formula (I), Z is N. In some embodiments of the compound of formula (I), Z is CR Z .

[0103] In some embodiments of the compound of Formula (I), R Z Hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 In some embodiments of the compound of Formula (I), R Z For hydrogen.

[0104] In some embodiments of the compound of formula (I), W is N. In some embodiments of the compound of formula (I), W is CRW .

[0105] In some embodiments of the compound of Formula (I), R W Hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 In some embodiments of the compound of Formula (I), R W For hydrogen.

[0106] In some embodiments of the compound of Formula (I), each R 1 are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally replaced by one or more R 1a substitution; or two R on the same atom 1 In some embodiments of the compound of Formula (I), each R 1 are independently deuterium, halogen, -ORa 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C 6 wherein each alkyl group is independently and optionally substituted by one or more R 1a substitution; or two R on the same atom 1 In some embodiments of the compound of Formula (I), each R 1 Independently -OR a 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b , C 1 -C 6 Alkyl or C 1 -C 6 haloalkyl; wherein each alkyl group is independently and optionally substituted by one or more R 1a substitution; or two R on the same atom 1 Together they form an oxo group.

[0107] In some embodiments of the compound of Formula (I), each R 1 Independently -OR a 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)ORb , C 1 -C 6 Alkyl or C 1 -C 6 haloalkyl; wherein each alkyl group is independently and optionally substituted by one or more R 1a In some embodiments of the compound of Formula (I), each R 1 Independently -NR c R d or optionally one or more R 1a Substituted C 1 -C 6 Alkyl; or two R on the same atom 1 In some embodiments of the compound of Formula (I), each R 1 Independently -NR c R d or optionally one or more R 1a Substituted C 1 -C 6 In some embodiments of the compound of Formula (I), each R 1 Independently -NR c R d ; or two R on the same atom 1 In some embodiments of the compound of Formula (I), each R 1 Independently -NR c R d In some embodiments of the compound of formula (I), each R 1 are independently optionally replaced by one or more R 1a Substituted C 1 -C 6 Alkyl; or two R on the same atom 1 Together they form an oxo group.

[0108] In some embodiments of the compound of Formula (I), each R 1 are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C6 wherein each alkyl, cycloalkyl and heterocycloalkyl group is independently and optionally substituted by one or more R 1a In some embodiments of the compound of Formula (I), each R 1 are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted by one or more R 1a In some embodiments of the compound of Formula (I), each R 1 are independently -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 aminoalkyl or heterocycloalkyl; wherein each alkyl and heterocycloalkyl is independently and optionally substituted by one or more R 1a In some embodiments of the compound of Formula (I), each R 1 are independently -OH, -NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 aminoalkyl or heterocycloalkyl; wherein each alkyl and heterocycloalkyl is independently and optionally substituted by one or more R 1a In some embodiments of the compound of Formula (I), each R 1 are independently and optionally replaced by one or more R 1a Substituted C 1 -C 6 In some embodiments of the compound of Formula (I), each R 1 Independently for C 1 -C 6 alkyl.

[0109] In some embodiments of the compound of Formula (I), each R1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compound of formula (I), each R 1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl or C 1 -C 6 wherein each alkyl group is independently and optionally substituted with one or more R. In some embodiments of the compound of formula (I), each R 1a are independently deuterium, halogen or C 1 -C 6 alkyl.

[0110] In some embodiments of the compound of Formula (I), each R 1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compound of formula (I), each R 1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C 6 wherein each alkyl group is independently and optionally substituted with one or more R. In some embodiments of the compound of formula (I), each R 1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C 6 In some embodiments of the compound of Formula (I), each R 1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl or C 1 -C 6 In some embodiments of the compound of formula (I), each R 1a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d or C 1 -C 6 In some embodiments of the compound of Formula (I), each R 1aare independently -CN or -NR c R d .

[0111] In some embodiments of compounds of formula (I), n is 1 to 4. In some embodiments of compounds of formula (I), n is 1 to 3. In some embodiments of compounds of formula (I), n is 1 or 2. In some embodiments of compounds of formula (I), n is 0 or 1. In some embodiments of compounds of formula (I), n is 0. In some embodiments of compounds of formula (I), n is 1. In some embodiments of compounds of formula (I), n is 2. In some embodiments of compounds of formula (I), n is 3.

[0112] In some embodiments of the compound of Formula (I), for

[0113]

[0114] In some embodiments of the compound of Formula (I), for

[0115]

[0116] In some embodiments of the compound of Formula (I), for

[0117]

[0118]

[0119] In some embodiments of the compound of Formula (I), for

[0120]

[0121] In some embodiments of the compound of Formula (I), for

[0122] In some embodiments of the compound of Formula (I), for

[0123] In some embodiments of the compounds disclosed herein, each R a Independently for C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1-C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a Independently for C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a Independently for C 1 -C 6 Alkyl, C 1 -C 6 wherein each alkyl and cycloalkyl group is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a Independently for C 1 -C 6 wherein each alkyl and cycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a Independently for C 1 -C 6 Alkyl or C 1 -C 6 wherein each alkyl group is independently and optionally substituted with one or more R.

[0124] In some embodiments of the compounds disclosed herein, each R b are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 wherein each alkyl and cycloalkyl group is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b are independently hydrogen, C 1 -C 6 wherein each alkyl and cycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b are independently hydrogen, C 1 -C 6 Alkyl or C 1 -C 6 wherein each alkyl group is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b is independently hydrogen or C independently and optionally substituted by one or more R 1 -C 6 alkyl.

[0125] In some embodiments of the compounds disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Deuterated alkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 wherein each alkyl and cycloalkyl group is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 wherein each alkyl and cycloalkyl is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 Alkyl or C 1 -C 6 wherein each alkyl group is independently and optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d is independently hydrogen or C independently and optionally substituted by one or more R 1 -C 6 In some embodiments of the compounds disclosed herein, R c is a cycloalkyl group and R d For hydrogen.

[0126] In some embodiments of the compounds disclosed herein, R c and R d Together with the atoms to which they are attached, they form a heterocycloalkyl group optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, R c and R d Together with the atoms to which they are attached they form a heterocycloalkyl.

[0127] In some embodiments of the compounds disclosed herein, each R is independently deuterium, halogen, -CN, -OH, -OC 1 -C 6 Alkyl, -NH 2 、-NHC 1 -C 6 Alkyl, -N(C 1 -C 6 alkyl) 2 、-C(=O)C 1 -C 6 Alkyl, -C(=O)OH, -C(=O)OC 1 -C 6 Alkyl, -C(=O)NH 2 、-C(=O)N(C 1 -C 6 alkyl) 2 、-C(=O)NHC 1 -C 6 Alkyl, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 or two R on the same atom form an oxo group. In some embodiments of the compounds disclosed herein, each R is independently deuterium, halogen, -CN, -OH, -OC 1 -C 6 Alkyl, -NH 2 、-NHC 1 -C 6 Alkyl, -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 or two R on the same atom form an oxo group. In some embodiments of the compounds disclosed herein, each R is independently deuterium, halogen, -CN, -OH, -OC 1 -C 6 Alkyl, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6or two R on the same atom form an oxo group. In some embodiments of the compounds disclosed herein, each R is independently deuterium, halogen, -CN, -OH, C 1 -C 6 Alkyl or C 1 -C 6 In some embodiments of the compounds disclosed herein, each R is independently halogen, C 1 -C 6 Alkyl or C 1 -C 6 In some embodiments of the compounds disclosed herein, each R is independently halogen or C 1 -C 6 Alkyl. In some embodiments of the compounds disclosed herein, each R is independently halogen.

[0128] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, one skilled in the art will select groups and substituents thereof to yield stable moieties and compounds.

[0129] In some embodiments, the compound disclosed herein is a compound selected from Table 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0130] Table 1

[0131]

[0132]

[0133]

[0134] *The stereochemistry at the chiral center is arbitrarily specified for other forms of the compounds disclosed herein

[0135] Isomers / stereoisomers

[0136] In some embodiments, the compounds described herein exist in the form of geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include all cis, trans, same side, opposite side, E-type (entgegen, E) and Z-type (zusammen, Z) isomers and their corresponding mixtures. In some cases, the compounds described herein have one or more chiral centers and each center exists in R configuration or S configuration. The compounds described herein include all diastereoisomers, enantiomers and epimers and their corresponding mixtures. In additional embodiments of the compounds and methods provided herein, the mixtures of enantiomers and / or diastereomers produced by a single preparation step, combination or mutual conversion are suitable for the applications described herein. In some embodiments, the compounds described herein are prepared as follows in the form of their individual stereoisomers: the racemic mixture of the compound is reacted with an optically active resolving agent to form a diastereomeric compound pair, the diastereomers are separated and the optically pure enantiomers are recovered. In some embodiments, dissociable complexes are preferred. In some embodiments, diastereomers have different physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by taking advantage of these differences. In some embodiments, diastereomers are separated by chiral chromatography or preferably by separation / analysis techniques based on solubility differences. In some embodiments, the optically pure enantiomers are then recovered by any practical means that do not cause racemization together with a resolving agent.

[0137] Labeled compounds

[0138] In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds in the form of pharmaceutical compositions. Therefore, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to the compounds listed herein, but for the fact that one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C. l5 N. 18 O. 17 O. 31 P. 32P. 35 S. 18 F and 36 Cl. Compounds described herein containing the aforementioned isotopes and / or other isotopes of other atoms and pharmaceutically acceptable salts, solvates or stereoisomers thereof are within the scope of the present invention. Certain isotopically labeled compounds, for example, and having 3 H and 14 Compounds containing a radioactive isotope of C are suitable for use in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred because of their ease of preparation and detectability. 2 Substitution of heavy isotopes with H) affords certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.

[0139] In some embodiments, the compounds described herein are labeled by other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0140] Pharmaceutically acceptable salts

[0141] In some embodiments, the compounds described herein exist in the form of pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts in the form of pharmaceutical compositions.

[0142] In some embodiments, the compounds described herein have acidic or basic groups and thus react with any of a variety of inorganic or organic bases and inorganic and organic acids to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein or their solvates or stereoisomers, or by reacting the purified compound in its free form with a suitable acid or base separately and isolating the salt thus formed.

[0143] Examples of pharmaceutically acceptable salts include those prepared by reacting the compounds described herein with inorganic acids, organic acids or inorganic bases, such salts include acetates, acrylates, adipates, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyne-1,4-dioate, camphorate, camphorsulfonate, hexanoate, octanoate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, gluconate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, gamma-hydroxybutyrate salt, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogen phosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmitate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and xylenesulfonate.

[0144] In addition, the compounds described herein can be prepared in the form of a pharmaceutically acceptable salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including but not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, Acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptanoic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid. In some embodiments, other acids (such as oxalic acid), while not pharmaceutically acceptable in themselves, are used to prepare salts that can be used as intermediates to obtain the compounds disclosed herein, their solvates or stereoisomers, and pharmaceutically acceptable acid addition salts thereof.

[0145] In some embodiments, those compounds described herein that contain free acid groups are reacted with a suitable base (such as a pharmaceutically acceptable metal cation hydroxide, carbonate, bicarbonate, sulfate), ammonia or a pharmaceutically acceptable organic primary, secondary, tertiary or quaternary amine. Representative salts include alkali metal salts or alkaline earth metal salts, such as lithium, sodium, potassium, calcium and magnesium salts, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 alkyl) 4 and their analogs.

[0146] Representative organic amines that can be used to form base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups contained therein. In some embodiments, water-soluble or oil-soluble or dispersible products are obtained from such quaternization.

[0147] Solvate

[0148] In some embodiments, the compounds described herein exist in the form of solvates. The present invention provides methods of treating diseases by administering such solvates. The present invention further provides methods of treating diseases by administering such solvates in the form of pharmaceutical compositions.

[0149] Solvates contain a stoichiometric or non-stoichiometric amount of solvent, and in some embodiments, are formed during a crystallization process with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein can be conveniently prepared or formed during the process described herein. By way of example only, hydrates of compounds described herein can be prepared by recrystallization from an aqueous / organic solvent mixture using an organic solvent including but not limited to dioxane, tetrahydrofuran, or methanol. In addition, compounds provided herein can exist in non-solvated and solvated forms. In general, for the purposes of compounds and methods provided herein, solvated forms are considered to be equivalent to non-solvated forms.

[0150] Tautomer

[0151] In some cases, compounds exist as tautomers. The compounds described herein include all possible tautomers within the chemical formulas described herein. Tautomers are compounds that can be interconverted by hydrogen atom migration, which is accompanied by the conversion of single bonds to adjacent double bonds. In the bond arrangements in which tautomerization can occur, a chemical equilibrium of tautomers will exist. All tautomeric forms of the compounds disclosed herein are encompassed. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH.

[0152] Treatment

[0153] Disclosed herein are methods of treating diseases in which inhibition of PTPN1 / PTPN2 is beneficial, the methods comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0154] Disclosed herein are methods of treating a disease in which inhibition of PTPN1 is beneficial, the methods comprising administering a compound disclosed herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, the disease in which inhibition of PTPN1 is beneficial is cancer or a metabolic disease.

[0155] Disclosed herein are methods of treating a disease in which inhibition of PTPN2 is beneficial, the methods comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the disease in which inhibition of PTPN2 is beneficial is cancer.

[0156] cancer

[0157] In some embodiments, the compounds disclosed herein, or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, are used to treat cancer.

[0158] As used herein, "cancer" refers to human cancers and epithelial cancers, sarcomas, adenocarcinomas (eg, papillary adenocarcinomas), lymphomas, leukemias, melanomas, etc., including solid cancers and lymphomas.

[0159] The term "leukemia" refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by aberrant proliferation and development of white blood cells and their precursors in the blood and bone marrow. Leukemias are generally clinically classified based on: (1) the duration and character of the disease - acute or chronic; (2) the cell types involved; myeloid (myelogenous), lymphoid (lymphoid), or monocytic; and (3) the presence or absence of an increase in the number of abnormal cells in the blood - leukemia or leukopenia (subleukemia). Exemplary leukemias that can be treated with the compounds, pharmaceutical compositions, or methods provided herein include, e.g., chronic leukemia, acute non-lymphocytic leukemia, acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, non-leukemic leukemia, leukocytic leukemia, basophilic leukemia, blastic leukemia, bovine leukemia, acute myeloid leukemia, chronic myeloid leukemia, leukemia cutis, embryonic leukemia, eosinophilic leukemia, erythroleukemia, Gross leukemia, hairy cell leukemia, hemoblastic leukemia, Hematoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphoid leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, granulocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Negley's leukemia, plasma cell leukemia, multiple myeloma, plasma cell leukemia, polycythemia vera, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia or undifferentiated cell leukemia.

[0160] The term "sarcoma" generally refers to a tumor composed of a substance such as embryonic connective tissue and generally composed of tightly packed cells embedded in a fibrous or homogeneous substance. Sarcomas that can be treated with the compounds, pharmaceutical compositions or methods provided herein include chondrosarcoma, fibrosarcoma, leiomyosarcoma, lymphosarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, liposarcoma, liposarcoma, alveolar sarcoma of soft tissue, ameloblastic sarcoma, botryoid sarcoma, green sarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, endothelial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, fibroblastic ... sarcoma), idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukemic sarcoma, malignant mesenchymal sarcoma, osteoblastic sarcoma, parosteal sarcoma, reticular cell sarcoma, Rous sarcoma, serous cystic sarcoma, synovial sarcoma, or telangiectatic sarcoma.

[0161] The term "epithelial cancer" refers to a malignant new growth composed of epithelial cells that tend to infiltrate surrounding tissues and give rise to metastases. Exemplary epithelial cancers that can be treated with the compounds, pharmaceutical compositions, or methods provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinar carcinoma, acinar carcinoma, adenoid cystic carcinoma, adenoid cystic carcinoma, adenomatous carcinoma, adrenocortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, basaloid cell carcinoma, basaloid carcinoma, basosquamous cell carcinoma, bile duct epithelial carcinoma, bladder epithelial carcinoma, breast epithelial carcinoma, Brenner's carcinoma, bronchioloalveolar carcinoma, bronchiolar carcinoma, bronchial carcinoma, encephaloid carcinoma, cervical carcinoma, cholangiocellular carcinoma, chordoma, choriocarcinoma, clear cell carcinoma, colloid epithelial carcinoma, colon carcinoma, comedo carcinoma, uterine corpus carcinoma, cribriform carcinoma, armored carcinoma, skin carcinoma, columnar carcinoma, columnar cell carcinoma, cystadenocarcinoma, ductal carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, medullary carcinoma, carcinoma), endometrioid carcinoma, epidermoid carcinoma, epithelial carcinoma, adenoid epithelial carcinoma, exophytic carcinoma, ulcerative carcinoma, fibrocarcinoma, colloid carcinoma, colloid carcinoma, giant cell carcinoma, giant cell carcinoma, adenocarcinoma, granulosa cell carcinoma, pilomatricoma, hematopoietic carcinoma, hepatocellular carcinoma, Hütter cell carcinoma, mucinous carcinoma (hyalinecarcinoma), adrenal carcinoma, immature embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompe-Kocher tumor, Kulczycki cell carcinoma, large cell carcinoma, lenticular carcinoma, lipomatous carcinoma, lobular carcinoma, lung carcinoma, lymphoepithelial carcinoma, medullary carcinoma (carcinoma medullare), medullary carcinoma, melanoma, soft carcinoma, mucinous carcinoma, mucinous carcinoma, mucinous cell carcinoma, mucoepidermoid carcinoma, mucosal carcinoma, mucoepithelioma, myxomatous carcinoma, nasopharyngeal carcinoma, nonpapillary renal cell carcinoma, oat cell carcinoma, ossifying carcinoma, bone carcinoma, ovarian carcinoma, pancreatic duct carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of the kidney, reserve cell carcinoma, sarcomatoid carcinoma, schneiderian carcinoma, scirrhous carcinoma carcinoma, scrotal carcinoma, sebaceous gland carcinoma, seminoma, serous carcinoma, signet ring cell carcinoma, simple carcinoma, small cell carcinoma, potato carcinoma, spheroid cell carcinoma, spindle cell carcinoma, cavernous carcinoma, squamous carcinoma, squamous cell carcinoma, rope carcinoma, sweat gland carcinoma, telangiectatic carcinoma, angioectatic carcinoma, transitional cell carcinoma, carcinoma tuberosum, tubular carcinoma, tuberous carcinoma, undifferentiated carcinoma, verrucous carcinoma, or villous carcinoma.

[0162] In some embodiments, the cancer is an acoustic neuroma, adrenocortical carcinoma, adrenal cancer, astrocytoma, benign monoclonal gammopathy, biliary tract cancer, bladder cancer, bone cancer, brain tumor, breast cancer, bronchial cancer, hematological tissue cancer, hepatic stellate cell carcinoma, oral or pharyngeal cancer, pancreatic stellate cell carcinoma, epithelial cancer, central nervous system cancer, cervical cancer, colon cancer, colorectal cancer, craniopharyngioma, ductal epithelial carcinoma, endocrine system cancer, endometrial cancer, ependymoma, epithelial ovarian cancer, esophageal cancer, gastric cancer, genitourinary tract cancer, glioblastoma multiforme, glioma, gynecological cancer, head and neck cancer, hemangioblastoma, Hodgkin's disease (Hodgkin's Disease), immune cell amyloidosis, kidney cancer, laryngeal cancer, leukemia, liver cancer (including hepatocellular carcinoma), lobular carcinoma, lung cancer, lymphoma, malignant carcinoid, malignant hypercalcemia, malignant insulinoma, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myeloma, endocrine or exocrine pancreatic tumors, neuroblastoma, non-Hodgkin lymphoma, oligodendroglioma, oral cancer, ovarian cancer, Paget's disease of the nipple Nipple, pancreatic cancer, papillary thyroid cancer, peripheral nervous system cancer, phyllodes tumor, pineal tumor, skin precancerous lesions, essential macroglobulinemia, essential thrombocythemia, prostate cancer, kidney cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer, small intestine or appendix cancer, stomach cancer, testicular cancer, thyroid cancer, bladder cancer, uterine cancer, Waldenstrom's macroglobulinemia.

[0163] Metabolic diseases

[0164] In some embodiments, the compounds disclosed herein, or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, are used to treat metabolic diseases.

[0165] As used herein, the term "metabolic disease" refers to a disease or condition that affects the metabolic process of a subject. Exemplary metabolic diseases include nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, heart disease, atherosclerosis, arthritis, cystinosis, diabetes (e.g., type I diabetes, type II diabetes or gestational diabetes), metabolic syndrome, phenylketonuria, proliferative retinopathy or Kearns-Sayredisease. In some embodiments, compounds disclosed herein are used to treat metabolic diseases (e.g., metabolic diseases described herein) by reducing or eliminating the symptoms of the disease. In some embodiments, methods of treatment include reducing or eliminating symptoms, including increased blood pressure, increased blood sugar levels, weight gain, fatigue, blurred vision, abdominal pain, flatulence, constipation, diarrhea, jaundice and the like.

[0166] dose

[0167] In certain embodiments, a composition containing a compound described herein is administered for therapeutic treatment. In certain therapeutic applications, the composition is administered to a patient who has a disease or condition in an amount sufficient to cure or at least partially inhibit at least one symptom of the disease or condition. The amount effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health, body weight, and response to the drug, and the judgment of the treating physician. The therapeutically effective amount is optionally determined by methods including, but not limited to, dose escalation and / or dose range clinical trials.

[0168] In certain embodiments where the patient's condition does not improve, the compound is administered chronically, i.e., for an extended period of time, including the entire duration of the patient's life, in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition, at the discretion of the physician.

[0169] In certain embodiments where the patient's condition improves, the dose of a medication being administered is temporarily reduced or temporarily suspended for a certain length of time (ie, a "drug holiday").

[0170] Once the patient's condition improves, a maintenance dose is administered as necessary. Subsequently, in a specific embodiment, the dose or frequency of administration, or both, is reduced depending on the symptoms.

[0171] The amount of a given agent corresponding to such an amount varies depending on factors such as the specific compound, the disease state and its severity, the identity of the subject or host in need of treatment (e.g., weight, sex), but is still determined by the specific circumstances surrounding it including, for example, the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.

[0172] In some embodiments, the dosage for adult treatment is generally in the range of 0.01 mg to 5000 mg per day. In some embodiments, the daily dosage suitable for the compound described herein or its pharmaceutically acceptable salt is about 0.01 to about 50 mg per kilogram of body weight. In various embodiments, the daily dose and unit dose vary depending on many variables, including but not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the needs of the individual subject, the severity of the disease or condition to be treated, and the judgment of the physician.

[0173] Route of administration

[0174] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, aural, nasal, and topical administration. In addition, parenteral delivery includes, by way of example only, intramuscular, subcutaneous, intravenous, intramedullary injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection.

[0175] In certain embodiments, the compounds as described herein are administered in a local rather than systemic manner, for example, often in the form of a reservoir preparation or a sustained release preparation by injecting the compound directly into an organ. In a specific embodiment, the long-acting preparation is administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. In addition, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with an organ-specific antibody. In such embodiments, the liposome is targeted to an organ and selectively absorbed by the organ. In other embodiments, the compounds as described herein are provided in the form of a rapid release preparation, in the form of an extended release preparation, or in the form of an intermediate release preparation.

[0176] Pharmaceutical compositions / preparations

[0177] The compounds described herein are administered to a subject in need thereof, alone or in combination with a pharmaceutically acceptable carrier, excipient, or diluent, in the form of a pharmaceutical composition, according to standard pharmaceutical practice. In some embodiments, the compounds described herein are administered to animals.

[0178] In another aspect, provided herein is a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof and at least one pharmaceutically acceptable excipient. The pharmaceutical composition is formulated in a conventional manner using one or more pharmaceutically acceptable excipients that aid in processing the active compound into a pharmaceutically usable preparation. The appropriate formulation depends on the selected route of administration. An overview of the pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H. A. and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Edition. (Lippincott Williams & Wilkins 1999), the disclosures of which are incorporated herein by reference.

[0179] In some embodiments, the pharmaceutically acceptable excipient is selected from a carrier, a binder, a filler, a suspending agent, a flavoring agent, a sweetener, a disintegrant, a dispersant, a surfactant, a lubricant, a colorant, a diluent, a solubilizer, a wetting agent, a plasticizer, a stabilizer, a penetration enhancer, a wetting agent, a defoaming agent, an antioxidant, a preservative, and any combination thereof.

[0180] The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[0181] combination

[0182] Disclosed herein are methods of treating cancer using a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an additional therapeutic agent.

[0183] In some embodiments, the additional therapeutic agent is an anti-cancer agent.

[0184] In some embodiments, the additional therapeutic agent is administered simultaneously with the compounds disclosed herein. In some embodiments, the additional therapeutic agent and the compounds disclosed herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered before the compounds disclosed herein are administered. In some embodiments, the additional therapeutic agent is administered after the compounds disclosed herein are administered.

[0185] In some embodiments, the additional therapeutic agent is an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[0186] Example

[0187] Example 1 and Example 2: (R)-5-(7-(2-aminoethyl)-1-fluoro-3-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide and (S)-5-(7-(2-aminoethyl)-1-fluoro-3-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0188]

[0189]

[0190] Step 1: General procedure for compounds 1-3

[0191] Triethylamine (398.7 g, 3.9 mol, 548 mL, 3.2 eq.) was added to a container containing formic acid (378 g, 7.8 mol, 6.4 eq.) at 0°C. 1-1 (250 g, 1.23 mol, 1 eq.) and 1-2 (177.4 g, 1.2 mol, 1 eq.) were then added thereto, which was then heated to 100°C and stirred for 12 hours. The reaction mixture was cooled to ambient temperature, followed by the addition of ice H 2 O (about 1 L). The resulting suspension was acidified with 6M HCl to adjust pH = 1. The precipitated crystals were filtered and then washed with water (500 mL×3). The precipitate was then resuspended in chloroform (500 mL) and Na 2 SO 4The mixture was then filtered and concentrated under reduced pressure to give 1-3 (377 g, 1.53 mol, 61% yield) as a light solid. 1 H NMR (400 MHz, CDCl 3 )δ7.35(d,J=7.8Hz,1H)7.09(m,1H)6.98-7.04(m,1H)3.13-3.17(m,2H)2.61-2.68(m,2H).

[0192] Step 2: General procedure for compounds 1-4

[0193] A solution of 1-3 (370 g, 1.50 mol, 1 eq.) in MeOH (1 L) was stirred at 0 °C for 5 min. Then SOCl was added dropwise 2 (534 g, 4.4 mol, 325 mL, 3 eq.), the temperature was maintained at 0°C, and then stirred for 2 hours. The resulting reaction mixture was filtered and concentrated under reduced pressure to obtain a crude material. The crude material was purified by column chromatography (SiO 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% RH, pH 7.5), petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 1-4 (300 g, 1.15 mol, 76% yield) as a brown oil. 1 H NMR (400 MHz, CDCl 3 )δ7.31(d,J=7.8Hz,1H)7.01-7.08(m,1H)6.94-7.00(m,1H)3.68(s,3H)3.11(m,2H)2.53-2.60(m,2H).

[0194] Step 3: General procedure for compounds 1-5

[0195] 1-4 (100 g, 383 mmol, 1 eq.) and Ti(Oi-Pr) 4 A solution of (152 g, 536 mmol, 158 mL, 1.4 eq) in THF (1 L) was cooled to 0 °C and stirred for 20 minutes. Then 3M EtMgBr (510 mL, 4 eq) was added thereto at 0 °C, followed by stirring for another 12 hours. The resulting reaction mixture was heated to room temperature by adding saturated NH 4 Cl (aqueous solution) (2 L) was quenched, followed by extraction with ethyl acetate (500 mL×4). The combined organic layers were washed with brine (1 L) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded 1-5 (50 g, 192 mmol, 50% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3)δ7.11(d,J=7.8Hz,1H)6.74-6.85(m,2H)2.84(td,J=7.75,2.25Hz,2H) 1.67-1.82(m,1H)1.57-1.63(m,2H)0.50-0.57(m,2H)0.16-0.23(m,2H).

[0196] Step 4: General procedure for compounds 1-6

[0197] To a solution of 1-5 (30 g, 115.78 mmol, 1 eq) in acetonitrile (300 mL) was added Pd(OAc) 2 (2.60 g, 11.5 mmol, 0.1 eq), K 3 PO 4 (49.1 g, 231 mmol, 2 eq.) and DPPB (9.88 g, 23 mmol, 0.2 eq.), which were then heated to 80 °C and stirred under N 2 The resulting reaction mixture was stirred for 12 hours. 2 O (150 mL), and then extracted with ethyl acetate (100 mL×3). The combined organic layers were washed with brine (100 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (50% CO, 40% RH, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to afford 1-6 (9.1 g, 51 mmol, 44% yield) as a brown oil. 1 H NMR (400 MHz, CDCl 3 )δ7.10-7.18(m,1H)6.94-7.03(m,2H)2.88-3.00(m,4H)2.60(m,4H).

[0198] Step 5: General procedure for compounds 1-8

[0199] At 25 °C, 1-6 (10.7 g, 60 mmol, 1 eq.) and 1-7 (18.5 g, 90 mmol, 1.5 eq.) were added to CH 2 Cl 2 TMSOTf (2.6 g, 12 mmol, 2.1 mL, 0.2 eq.) was added to the solution in 1% ethanol (200 mL) and stirred for 12 h. The resulting reaction mixture was heated to 40 °C by adding H 2 O (100 mL), and then extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (50 mL × 3) and purified by Na 2 SO 4Drying, followed by filtration and concentration under reduced pressure gave the crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% RH, pH 7.0) to afford 1-8 (11 g, 49 mmol, 82% yield) as a brown oil. 1 H NMR (400 MHz, CDCl 3 )δ7.07(m,1H)6.87-6.96(m,2H)4.03(s,4H)2.79-2.93(m,4H)1.82(br d,J=8.0Hz,4H).

[0200] Step 6: General procedure for compounds 1-10

[0201] To a solution of 1-8 (5 g, 22 mmol, 1 eq.) in THF (50 mL) were added 1-9 (11.4 g, 44 mmol, 2 eq.), iridium chloride; (1Z,5Z)-cycloocta-1,5-diene (1.5 g, 2.2 mmol, 0.1 eq.), 4-tert-butyl-2-(4-tert-butyl-2-pyridyl) and pyridine (1.8 g, 6.7 mmol, 0.3 eq.), which was then heated to 70 °C and stirred under N 2 The resulting reaction mixture was cooled to 25°C and then slowly added with H 2 O (1 L). Then brine (400 mL) was added thereto, followed by extraction with ethyl acetate (200 mL×3). The combined organic phases were purified by Na 2 SO 4 The mixture was dried, filtered and concentrated under reduced pressure to give a yellow oil. 2 The crude material was purified by HPLC (5% CO 2 , petroleum ether / ethyl acetate=1 / 0 to 10 / 1) to give a light-colored oil (30 g, crude material). 1 H NMR (400 MHz, CDCl 3 )δ7.13-7.43(m,2H)3.91(s,4H)2.69-2.83(m,4H)1.62-1.74(m,4H)1.22-1.28(m,12H).

[0202] Step 7: General procedure for compounds 1-11

[0203] To a solution of 1-10 (32 g, 91 mmol, 1 eq) in acetone (300 mL) was added potassium monopersulfate (112 g, 183 mmol, 2.0 eq) in H2O dropwise at 0 °C over 15 min. 2 O (300 mL). It was then stirred for another 10 minutes. The resulting reaction mixture was stirred by adding H 2O (1 L), and then extracted with ethyl acetate (500 mL × 3). The combined organic layer was washed with brine (100 mL × 3) and 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% NH 2 4 ... 1 H NMR (400 MHz, CDCl 3 )δ6.69-6.81(m,1H)6.38-6.44(m,1H)4.02(d,J=2.3Hz,4H)2.67-2.91(m,4H)1.79(br d,J=8.6Hz,4H)1.24-1.30(m,4H).

[0204] Step 8: General procedure for compounds 1-12

[0205] To a solution of 1-11 (41 g, 172 mmol, 1 eq.) in THF (300 mL) was added NaH (13.7 g, 344 mmol, 60% purity, 2 eq.) at 0 °C and stirred at N 2 5% NH4Cl (32.1 g, 258 mmol, 29.4 mL, 1.5 eq.) was then added dropwise. The reaction mixture was warmed to 25°C and stirred for 12 hours. 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 The resulting suspension was quenched with a mixture of 4% paraformaldehyde (1:1, 600 mL) and 1% paraformaldehyde (1:1, 600 mL). The reaction mixture was stirred at 25 °C for 5 minutes and then extracted with ethyl acetate (330 mL x 3). The combined organic layers were washed with H 2 O (600 mL) and brine (600 mL), 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% RH, pH 7.5) to afford 1-12 (31 g, 94 mmol, 68% yield) as a colorless oil. 1 HNMR (400MHz, CDCl 3)δ6.71-6.91(m,1H)6.53-6.60(m,1H)5.12-5.20(m,2H)3.92(s,4H)3.77-3.82(m,1H)3.70-3.76(m,1H)3.44-3.50(m,2H)3.27-3.31(m,3H)2.63-2.81(m,4H)1.70(br d,J=7.7Hz,4H). Step 9: General procedure for compounds 1-13

[0206] To a solution of 2,2,6,6-tetramethylpiperidine (2.3 g, 16 mmol, 2.8 mL, 2 eq.) in THF (20 mL) was added 2.5 M n-BuLi (6.6 mL, 2 eq.) at 0 °C and stirred at N 2 The reaction mixture was then cooled to -78 °C, and then a solution of 1-12 (2.7 g, 8.2 mmol, 1 eq) in THF (10 mL) was added, followed by TMEDA (1.4 g, 12.4 mmol, 1.87 mL, 1.5 eq) and stirred for another 2 hours. Then 1 was added 2 (5.2 g, 20 mmol, 4.17 mL, 2.5 equiv) in THF (5 mL) and stirred for another hour. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1MNa 2 S 2 O 3 (aqueous solution) (1:1, 30 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (20 mL) and brine (20 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% RH, pH 7.5), to afford 1-13 (2.8 g, 6.19 mmol, 74% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl 3 )δ6.77(s,1H),5.32(s,2H),4.01(s,4H),3.90-3.85(m,2H),3.60-3.55(m,2H),3.39(s,3H),2.88-2.76(m,4H),1.83-1.73(m,4H). Step 10: General procedure for compounds 1-15

[0207] To a solution of 1-13 (1 g, 2.2 mmol, 1 eq.) in 1,4-dioxane (10 mL) were added 1-14 (435 mg, 3.3 mmol, 1.5 eq.), Cs 2 CO 3 , (2.1 g, 6.6 mmol, 3 eq), XPhos (210 mg, 442 μmol, 0.2 eq) and BrettPhos Pd G 3 (200 mg, 221 μmol, 0.1 eq.), which was then heated to 100 °C and stirred for 48 h. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 200 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (100 mL×5). The combined organic layers were washed with water (300 mL) and brine (200 mL) and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% NH 2 O), petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to afford 1-15 (16.8 g, 36 mmol, 61% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ6.73(s,1H)5.24-5.31(m,2H)4.00(s,4H)3.95(s,2H)3.86(m,2H)3.58(m,2H)3.39(s,3H)2.67-2.79(m,4H)1.72-1.80(m,4H)1.44(s,9H).

[0208] Step 11: General procedure for compounds 1-16

[0209] At 0°C, N-(oxymethylene)sulfamoyl chloride (1.9 g, 13.8 mmol, 1.2 mL, 1.5 equiv) was added to CH 2 Cl 2 To a solution of prop-2-en-1-ol (1.65 g, 28.4 mmol, 1.93 mL, 3.08 eq.) in CH4 (30 mL) was added and stirred for 0.5 h. 1-15 (4.2 g, 9.2 mmol, 1 eq.) and DIPEA (2.38 g, 18.4 mmol, 3.2 mL, 2 eq.) were then added at 25 °C. 2 Cl 2(30 mL) and stirred for 1 hour. To the resulting reaction mixture was added H 2 O (150 mL), followed by CH 2 Cl 2 The combined organic layers were washed with brine (100 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% NH 2 O), petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to afford 1-16 (17.8 g, 28 mmol, 78% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ8.37(s,1H)6.84(s,1H)5.24-5.41(m,6H)4.64-4.70(m,3H)4.22(d,J= 17.8Hz,1H)4.00(s,4H)3.86(m,2H)3.51-3.59(m,2H)3.33(s,3H)2.79(br s,4H)1.69-1.86(m,4H)1.42(s,9H).

[0210] Step 12: General procedure for compounds 1-17

[0211] To a solution of 1-16 (1 g, 1.62 mmol, 1 eq) in MeOH (10 mL) were added NaOMe (1.46 g, 8.08 mmol, 30% purity, 5 eq) and Pd(PPh 3 ) 4 (186 mg, 161 μmol, 0.1 eq), which was then heated to 60° C. and stirred for 1 hour. The resulting reaction mixture was then filtered and concentrated under reduced pressure to give 1-17 (13.05 g, crude) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ6.87(s,1H)5.31(s,2H)4.35-4.44(m,2H)4.01(s,4H)3.80-3.92(m,3H)3.46-3.61(m,3H)3.35-3.40(m,3H)2.79(br s,4H)1.72-1.85(m,4H).

[0212] Step 13: General procedure for compounds 1-18

[0213] A solution of 1-17 (0.8 g, 1.74 mmol, 1 eq.) in formic acid (8 mL) was stirred at 25 °C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was used in the next step without further purification. 1-18 (800 mg, crude) was obtained as a yellow solid. LCMS (ESI-): m / z=415.2 (MH) - .

[0214] Step 14: General procedure for compounds 1-19

[0215] To a solution of 2-diethoxyphosphorylacetonitrile (957 mg, 5.4 mmol, 874 μL, 1.5 eq.) in THF (10 mL) was added NaH (216 mg, 5.4 mmol, 60% purity, 1.5 eq.) and the mixture was stirred at 0 °C under N 2 Then, a solution of 1-18 (1.5 g, 3.6 mmol, 1 eq.) in THF (5 mL) was added and stirred at 25° C. for another 2 hours. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 10 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (10 mL) and brine (10 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded 1-19 (2 g, crude) as a yellow oil.

[0216] Step 15: General procedure for compounds 1-20

[0217] To a solution of 1-19 (1.5 g, 3.41 mmol, 1 eq.) in MeOH (10 mL) was added Pd / C (0.7 g, 10% purity), followed by H 2 The reaction mixture was then heated to 40 ° C and stirred for 12 hours. The resulting reaction mixture was then filtered through diatomaceous earth and concentrated under reduced pressure to give a crude material. The crude material was then purified by preparative HPLC to give 1-20 (0.2 g, 453 μmol, 13% yield) as a white solid. 1-20A and 1-20B (stereochemistry at the chiral center is arbitrarily specified) were obtained by SFC separation of 1-20.

[0218] Step 16: General procedure for compounds 1-21

[0219] In N 2To a solution of 1-20A or 1-20B (40 mg, 90 μmol, 1 eq.) in EtOH (2 mL) was added NH 3 -H 2 O (12 mg, 90 μmol, 13 μL, 26% purity, 1 eq.) and Raney-nickel (0.02 g). 2 The reaction mixture was purged with 50 psi and then heated to 40 °C and stirred for 12 h. The resulting reaction mixture was then filtered through celite and concentrated under reduced pressure to afford 1-21A or 1-21B (40 mg, crude) as a yellow solid.

[0220] Step 17: General procedure for Examples 1 and 2

[0221] A solution of 1-21A (20 mg, 44 μmol, 1 eq.) in 4M HCl / dioxane (1 mL, 89 eq.) was stirred at 20 °C for 1 hour. The reaction mixture was then concentrated under reduced pressure to give the crude material. The crude material was then purified by preparative HPLC to give Example 1 (5.8 mg, 16 μmol, 36% yield). LCMS (ESI-): m / z=356.1 (MH) - . 1 H NMR (400 MHz, DMSO-d 6 )δ9.88-9.61(m,1H),7.77(br s,2H),6.55(s,1H),4.22(s,2H),3.04-2.92(m,1H),2.88-2.76(m,2H),2.76-2.60(m,2H),2.37(br t,J=13.3Hz,1H),1.95-1.81(m,2H),1.71(br d,J=6.3Hz,1H),1.55-1.42(m,2H),1.11-0.88(m,2H).

[0222] Similarly, Example 2 was obtained: LCMS (ESI-): m / z=356.0 (MH) - . 1 H NMR (400 MHz, DMSO-d 6 )δ6.49(s,1H)3.91(s,2H)2.93-3.03(m,1H)2.75-2.88(m,2H)2.64-2.71(m,2H)2.41(s,1H)1.86(br dd,J=10.9,3.3Hz,2H)1.63-1.76(m,1H)1.39-1.52(m,2H)0.91-1.11(m,2H).

[0223] Example 3 - Example 22: Compounds were prepared according to the procedures described in 1-22 using the appropriate amines.

[0224]

[0225] Step 1: General procedure for compounds 1-22

[0226] To a solution of 1-18 (100 mg, 240 μmol, 1 eq.) in acetonitrile (1 mL) were added the corresponding amine (1 eq.) and NaBH 3 CN (45 mg, 720 μmol, 12 μL, 3 eq) and stirred at 25 °C for 12 hours. The resulting reaction mixture was then concentrated under reduced pressure to give a crude material. The crude material was then purified by HPLC to give 1-22. The separation of enantiomers was obtained by SFC separation of 1-22.

[0227] Step 2: General procedure for Examples 3-22

[0228] A solution of 1-22 (1 equivalent) in 4M HCl / ethyl acetate (1 mL) was stirred at 25°C for 2 hours. The reaction mixture was then concentrated under reduced pressure to give a crude material. The crude material was purified by HPLC (column: Waters Xbridge BEH C18 100×30 mm×10 um; mobile phase: [A:H 2 O(NH 4 HCO 3 ), B: acetonitrile]; B: 1-15%, 8 minutes), to obtain Example 3-Example 22.

[0229]

[0230]

[0231] Example 23 and Example 24: (S)-5-(1-fluoro-3-hydroxy-7-((methylamino)methyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide and (R)-5-(1-fluoro-3-hydroxy-7-((methylamino)methyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0232]

[0233] Step 1: General procedure for compounds 1-23

[0234] To a solution of methoxymethyl(triphenyl)phosphonium chloride (1.98 g, 5.76 mmol, 1.5 eq) in THF (15 mL) was added t-BuOK (1 M, 11.53 mL, 3 eq) at 0 °C and stirred at N 2 Then 1-18 (1.6 g, 3.84 mmol, 1 eq.) was added thereto and the mixture was heated to 25°C and stirred for another 0.5 h. H 2 O (15 mL), and then extracted with ethyl acetate (5 mL×3). The combined organic layers were washed with brine (10 mL) and purified by Na 2 SO 4 Drying, filtration, and subsequent concentration under reduced pressure afforded the crude material. The crude material was then purified by column chromatography (SiO 2 The crude material was purified by HPLC (HPLC: 500 % by mass 4% CO, ethyl acetate / methanol = 1 / 0 to 3 / 1) to afford 1-23 (1 g, 2.25 mmol, 58% yield) as a yellow solid. 1 H NMR (400MHz, CD 3 OD)δ6.89(d,J=4.38Hz,1H)5.91(d,J=2.50Hz,1H)5.28(d,J=1.13Hz,2H)4.26(s,2H)3.81-3.88(m,2H)3.56(br d,J=5.13Hz,2H)3.33(s,3H)2.76(br dd,J=10.44,4.94Hz,4H)2.28-2.39(m,2H)2.05-2.16(m,2H).

[0235] Step 2: General procedure for compounds 1-24

[0236] 1-23 (0.3 g, 674 μmol, 1 eq.) was reacted with CH 2 Cl 2 To a solution in 4% paraformaldehyde (2 mL), TFA (837 mg, 7.3 mmol, 545 μL, 10.8 equiv) was added and stirred at 0° C. for 15 min. The reaction mixture was then concentrated under reduced pressure to give 1-24 (0.9 g, crude) as a yellow solid.

[0237] Step 3: General procedure for compounds 1-25

[0238] To 2M methylamine (33.8 mL, 145 equiv.) in CH 2 Cl 2 1-24 (0.2 g, 464 μmol, 1 eq.) and diisopropylethylamine (120 mg, 929 μmol, 161 μL, 2 eq.) were added to a solution in 4% paraformaldehyde (2 mL) and stirred at 25° C. for 0.5 h. NaBH3 CN (58 mg, 929 μmol, 2 eq) was added and stirred for another 0.5 h. 1 M HCl (0.5 mL) and H 2 O (15 mL), followed by CH 2 Cl 2 The combined organic layers were washed with brine (10 mL) and purified by Na 2 SO 4 Drying followed by filtration and concentration under reduced pressure gave the crude material.

[0239] Step 4: General procedure for compounds 1-25A and 1-25B

[0240] The crude material was purified by HPLC to afford 1-25 (0.02 g, 44 μmol, 9% yield) as a yellow solid. SFC separation of 1-25 afforded 1-25A and 1-25B (stereochemistry at the chiral center was assigned arbitrarily). 1 H NMR (400MHz, CD 3 OD)δ6.89(s,1H)5.28(s,2H)4.23(s,2H)3.82-3.88(m,2H)3.52-3.58(m,2H)3.33(s,3H)3.20(br dd,J=14.88,7.0Hz,1H)2.80-2.92(m,4H)2.72(s,3H)2.43-2.55(m,1H)1.95-2.15(m,3H)1.06-1.23(m,2H).

[0241] Step 5: General procedure for Examples 23 and 24

[0242] A solution of 1-25A (20 mg, 44 μmol, 1 eq) in 4M HCl / EtOAc (1 mL) was stirred at 20 °C for 0.5 h. The reaction mixture was then concentrated under reduced pressure to give the crude product. The crude product was triturated with ethyl acetate (0.5 mL) to give Example 23 (5 mg, 12 μmol, 26% yield) as a white solid. LCMS (ESI+): m / z=358.1 (M+H) + . 1 H NMR (400 MHz, DMSO-d 6)δ9.28(br d,J=1.8Hz,1H),8.25(br d,J=1.8Hz,2H),6.53(s,1H),4.02(s,2H),2.99(br dd,J=14.5,6.9Hz,1H),2.77-2.84(m,2H),2.72(br d,J=5.9Hz,2H),2.54-2.58(m,3H),2.35-2.45(m,1H),1.86-2.03(m,3H),1.00-1.14(m,2H).

[0243] Example 24: LCMS (ESI+): m / z=358.1 (M+H) + . 1 H NMR (400 MHz, DMSO-d 6 )δ9.88(br d,J=1.88Hz,1H),8.36(br d,J=1.8Hz,2H),6.55(s,1H),4.22(s,2H),2.97(br dd,J=14.5,6.9Hz,1H),2.71-2.80(m,4H),2.54-2.56(m,4H),1.90-1.98(m,3H),1.05-1.08(m,2H).

[0244] Example 25: 5-(1-Fluoro-3-hydroxy-8-(isopentylamino)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0245] Example 26 and Example 27: (S)-5-(1-fluoro-3-hydroxy-8-(isopentylamino)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide and (R)-5-(1-fluoro-3-hydroxy-8-(isopentylamino)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0246]

[0247] Step 1: General procedure for compound 25-2

[0248] To a solution of 25-1 (20 g, 97.55 mmol, 1 eq), but-3-enoic acid (20.6 g, 239 mmol, 2.46 eq), tri-o-tolylphosphine (5.94 g, 19.5 mmol, 0.2 eq) and triethylamine (49.3 g, 487 mmol, 67 mL, 5 eq) in DMA (200 mL) was added Pd(OAc) 2 (2.19 g, 9.75 mmol, 0.1 eq.), which was then heated to 120 °C and stirred under N 2 The mixture was stirred for 12 hours. Brine (400 mL) was then added to the resulting reaction mixture, followed by extraction with ethyl acetate (300 mL×3). The combined organic layers were washed with brine (800 mL×5) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% ethanol, 0.2% CO, 0.3% ethanol, 1.2% ethanol, 0.4% ethanol, 0.6% ethanol, 1.2% ethanol, 0.8% ethanol, 1.3% ethanol, 0.9% ethanol, 1.4% ethanol, 0.9% ethanol, 1.2% ethanol, 0.8% ethanol, 1.3% ethanol, 0.8% ethanol, 1.4% ethanol, 1.5% ethanol, 0.8 ...2% ethanol, 1.4% ethanol, 1.5% ethanol, 1. 1 H NMR (400MHz, CD 3 OD)δ6.77-6.70(m,2H),6.55(td,J=2.3,10.6Hz,1H),6.49-6.42(m,1H),6.40-6.30(m,1H),3.80(s,3H),3.23(dd,J=1.1,6.9Hz,2H).

[0249] Step 2: General procedure for compound 25-3

[0250] In N 2 Pd / C (6 g, 10% purity) was added to a solution of 25-2 (18.1 g, 86 mmol, 1 eq) in THF (300 mL) under reduced pressure. 2 The reaction mixture was purged with 50 psi and stirred for 12 h. The reaction mixture was then filtered and concentrated under reduced pressure to afford 25-3 (14.2 g, 66.91 mmol, 77% yield) as a yellow oil. 1 H NMR (400MHz, CD 3 OD) δ6.59 (s, 1H), 6.55-6.47 (m, 2H), 3.77 (s, 3H), 2.62 (t, J = 7.6 Hz, 2H), 2.30 (t, J = 7.3 Hz, 2H), 1.89 (quintet, J = 7.5 Hz, 2H).

[0251] Step 3: General procedure for compound 25-4

[0252] A solution of 25-3 (14.2 g, 66 mmol, 1 eq.) in PPA (71 g) was heated to 100 °C and stirred for 5 hours. Saturated NaOH (aqueous solution) (500 mL) was then added to the resulting reaction mixture and stirred for another 5 minutes. The aqueous phase was then extracted with ethyl acetate (400 mL x 3). The combined organic phases were washed with brine (1 L) and washed with Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% ethanol / ethyl acetate = 4 / 1 to 2 / 1) to give 25-4 (4.86 g, 25 mmol, 37% yield) as a yellow solid. 1 HNMR (400MHz, CD 3 OD) δ6.69 (s, 1H), 6.60 (dd, J = 2.4, 13.5 Hz, 1H), 3.86 (s, 3H), 2.96 (t, J = 6.0 Hz, 2H), 2.62-2.52 (m, 2H), 2.06 (quintet, J = 6.3 Hz, 2H).

[0253] Step 4: General procedure for compound 25-5

[0254] To a solution of 25-4 (4.7 g, 24.20 mmol, 1 eq.) in toluene (47 mL) was added AlCl 3 (9.68 g, 72.6 mmol, 3.97 mL, 3 equivalents), which was then heated to 110 ° C and stirred for 30 minutes. The reaction mixture was then poured into ice water (w / w=1 / 1, 40 mL) and stirred for another 5 minutes. The aqueous phase was then extracted with ethyl acetate (25 mL×3). The combined organic phase was washed with brine (30 mL) and washed with Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave the crude material. 2 The crude material was purified by HPLC (HPLC: 50 °C, 5% by weight, petroleum ether / ethyl acetate = 1 / 1, Rf = 0.3) to give 25-5 (3.5 g, 19.4 mmol, 80% yield) as a yellow solid.

[0255] Step 5: General procedure for compound 25-6

[0256] To a solution of 25-5 (2.1 g, 11.6 mmol, 1 eq.) in DMF (20 mL) were added BnBr (2.39 g, 13.9 mmol, 1.66 mL, 1.2 eq.) and K 2 CO 3(3.22 g, 23 mmol, 2 eq.) and stirred at 25 °C for 2 h. H 2 O (30 mL), and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (15 mL × 3) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (50 / 1 to 25 / 1) to afford 25-6 (3 g, 11.10 mmol, 95% yield) as a yellow oil.

[0257] Step 6: General procedure for compound 25-7

[0258] To a solution of 25-6 (4 g, 14.8 mmol, 1 eq) in THF (40 mL) was added methyl(triphenyl)phosphonium bromide (12.6 g, 35.52 mmol, 2.4 eq) dropwise followed by 1M t-BuOK (35.5 mL, 2.4 eq) and then stirred at 20 °C under N 2 To the resulting reaction mixture was added H 2 O (30 mL), and then extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (45 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave the crude material. 2 The crude material was purified by HPLC-MS / MS (HPLC-MS / MS): 5040-400 μL (w / v / v 4040 MHz, CDCl 25-4040 MHz, 10.4 % CO 2 , petroleum ether / ethyl acetate=10 / 1, Rf=0.4) to give 25-7 (3.9 g, 14.5 mmol, 98% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ7.50-7.31(m,5H),6.61(d,J=1.9Hz,1H),6.52(dd,J=2.5,13.7Hz,1H), 5.77-5.67(m,1H),5.04(s,2H),2.67(t,J=7.6Hz,2H),2.21-2.10(m,5H).

[0259] Step 7: General procedure for compounds 25-8

[0260] To a solution of 25-7 (2.9 g, 10.8 mmol, 1 eq) in MeOH (45 mL) was added [hydroxy(phenyl)-λ3-iodanyl]4-methylbenzenesulfonate (4.24 g, 10.81 mmol, 1 eq) and stirred at 20 °C for 1 hour. The reaction mixture was then concentrated under reduced pressure to give a crude material. The product was then purified by column chromatography (SiO 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% NH 2 O), to afford 25-8 (1.5 g, 5.28 mmol, 48% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl 3 )δ7.50-7.31(m,5H),6.70-6.55(m,2H),5.04(s,2H),3.68(s,2H),2.92-2.82(m,2H),2.54(t,J=7.0Hz,2H),2.00(quintet,J=6.8Hz,2H).

[0261] Step 8: General procedure for compounds 25-9

[0262] To a solution of 25-8 (450 mg, 1.58 mmol, 1 eq.) in DCE (10 mL) was added 3-methylbutan-1-amine (206.93 mg, 2.37 mmol, 275.91 μL, 1.5 eq.) and stirred at 25 °C for 1 hour. Then NaBH(OAc) was added thereto. 3 (1.01 g, 4.75 mmol, 3 eq.) and stirred for another 2 h. H 2 O (10 mL), and then extracted with ethyl acetate (5 mL×3). The combined organic layers were washed with brine (10 mL) and purified by Na 2 SO 4 Drying, subsequent filtration and concentration under reduced pressure afforded 25-9 (560 mg, crude) as a yellow oil.

[0263] Step 9: General procedure for compounds 25-10

[0264] To a solution of 25-9 (560 mg, 1.58 mmol, 1 eq) in THF (15 mL) was added Boc 2 O (688 mg, 3.15 mmol, 723 μL, 2 eq.) and triethylamine (478 mg, 4.7 mmol, 657 μL, 3 eq.) were added and stirred at 25 °C for 12 h. To the resulting reaction mixture was added H 2 O (20 mL), and then extracted with ethyl acetate (15 mL×3). The combined organic layers were washed with brine (20 mL) and purified by Na2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 , petroleum ether / ethyl acetate=3% ethyl acetate) to give 25-10 (580 mg, 1.27 mmol, 80% yield) as a yellow oil.

[0265] Step 10: General procedure for compounds 25-11

[0266] To a solution of 25-10 (580 mg, 1.2 mmol, 1 eq) in THF (10 mL) was added 2.5 M n-BuLi (1.02 mL, 2 eq) dropwise at -78 °C, followed by N 2 Then add 1 2 (646 mg, 2.55 mmol, 512 μL, 2 equiv) in THF (5 mL) and stirred for another 1 h. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) (15 mL) was quenched, followed by extraction with ethyl acetate (5 mL×2). The combined organic layers were washed with brine (15 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave the crude material. 2 The crude material was purified by HPLC-MS / MS (HPLC-MS / MS): 50444-0.7544 (Additive No. 4582776A, 404477A, ​​5 ... 1 HNMR (400MHz, CDCl 3 )δ7.50(d,J=7.3Hz,2H),7.41(t,J=7.4Hz,2H),7.37-7.31(m,1H),6.47(s,1H),5.14(d,J=2.3 Hz, 2H), 3.54-2.51 (m, 7H), 2.37-1.85 (m, 3H), 1.53-1.20 (m, 13H), 0.94 (dd, J = 0.8, 6.6Hz, 6H).

[0267] Step 11: General procedure for compounds 25-12

[0268] To a solution of 25-11 (180 mg, 309 μmol, 1 eq.) in 1,4-dioxane (9 mL) were added tert-butyl 2-aminoacetate (60 mg, 464 μmol, 1.5 eq.) and Cs 2 CO 3 (201 mg, 619 μmol, 2 eq.), then degassed in vacuo and heated with N 2The mixture was purged 3 times. BrettPhos Pd G3 (28 mg, 30 μmol, 0.1 eq.) was then added and vacuum degassed again, and the mixture was heated with N 2 The reaction mixture was then heated to 90°C and stirred for 16 hours. The resulting reaction mixture was then concentrated under reduced pressure to give a crude product. The product was then purified by column chromatography (SiO 2 The crude material was purified by HPLC-MS / MS (50% by weight, 1% by weight, petroleum ether / ethyl acetate = 5 / 1) to give 25-12 (130 mg, 222 μmol, 71% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl 3 )δ7.54-7.21(m,5H),6.52-6.24(m,1H),5.13-4.93(m,2H),3.49-2.43(m,7H),2.21-2.0 3(m,1H),1.95-1.86(m,2H),1.77-1.43(m,10H),1.42-1.35(m,10H),0.88-0.82(m,6H).

[0269] Step 12: General procedure for compounds 25-13

[0270] N-(Oxymethylene)sulfamoyl chloride (135 mg, 957 μmol, 83 μL, 2 equiv.) was dissolved in CH 2 Cl 2 Prop-2-en-1-ol (55 mg, 957 μmol, 65 μL, 2 eq.) was added to a solution of 1% paraformaldehyde (5 mL) and the mixture was stirred at 0 °C under N 2 Then 25-12 (280 mg, 478 μmol, 1 eq.) and triethylamine (145 mg, 1.44 mmol, 199 μL, 3 eq.) were added to the mixture in CH 2 Cl 2 (5 mL) and stirred for another 0.5 h. The reaction mixture was then warmed to 25 °C and stirred for another 1 h. To the resulting reaction mixture was added H 2 O (20 mL), followed by CH 2 Cl 2 The combined organic layers were washed with brine (30 mL) and purified by Na 2 SO 4 Drying, subsequent filtration and concentration under reduced pressure afforded 25-13 (400 mg, crude) as a yellow oil.

[0271] Step 13: General procedure for compounds 25-14

[0272] To a mixture of 25-13 (50 mg, 66 μmol, 1 eq.) and MeOH (1 mL) were added NaOMe (60 mg, 334 μmol, 30% purity, 5 eq.), Pd(PPh 3 ) 4 (7.7 mg, 6.7 μmol, 0.1 eq.), which was then heated to 60 °C and stirred at N 2 The mixture was stirred for 1 hour. 0.5 M HCl (5 mL) was then added to the resulting reaction mixture, followed by extraction with ethyl acetate (5 mL×3). The combined organic layers were washed with brine (10 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded 25-14 (45 mg, crude) as a yellow oil.

[0273] Step 14: General procedure for compound 25-15

[0274] A mixture of 25-14 (45 mg, 76 μmol, 1 eq.) in HCl / ethyl acetate (3 mL) was stirred at 25° C. for 0.5 h. The resulting reaction mixture was then concentrated under reduced pressure to give 25-15 (40 mg, 76 μmol, 99% yield, HCl) as a yellow oil.

[0275] Step 15: General Procedure for Example 25

[0276] To a solution of 25-15 (30 mg, 61 μmol, 1 eq.) in MeOH (5 mL) was added Pd / C (10 mg, 10% purity), followed by HCl. 2 (15 psi) was purged and stirred at 25°C for 16 hours. The reaction mixture was then filtered and concentrated under reduced pressure to give a crude material. The crude material was then purified by preparative HPLC to give Example 25 (3.3 mg, 8.3 μmol, 13% yield). 1 HNMR (400MHz, CD 3 OD)δ6.59(s,1H),4.24(s,2H),3.25-3.00(m,4H),2.96-2.70(m,3H),2.37-2.20(m,1H),2 .07-1.81(m,2H),1.77-1.65(m,1H),1.57(td,J=6.0,10.1Hz,3H),0.98(d,J=6.5Hz,6H).

[0277] Step 16: General procedure for Examples 26 and 27

[0278] Examples 26 and 27 were obtained by SFC separation of Example 25 (stereochemistry at the chiral center was assigned arbitrarily).

[0279] Example 26: LCMS (ESI-): m / z=398.2 (MH) - . 1 H NMR (400 MHz, D 2 O)δ6.67(s,1H),4.34(s,2H),3.37-3.25(m,1H),3.20(br d,J=14.9Hz,1H),3.16-2.97(m,3H),2.77(br d,J=4.5Hz,2H),2.28-2.14(m,1H),1.99-1.80(m,2H),1.72-1.43(m,4H),0.89(d,J=6.6Hz,6H).

[0280] Example 27: LCMS (ESI-): m / z=398.2 (MH) - . 1 H NMR (400 MHz, D 2 O)δ6.62(s,1H),4.29(s,2H),3.29-3.20(m,1H),3.15(br d,J=14.4Hz,1H),3.10-2.91(m,3H),2.72(br d,J=4.1Hz,2H),2.21-2.08(m,1H),1.93-1.75(m,2H),1.64-1.41(m,4H),0.84(d,J=6.5Hz,6H)

[0281] Example 28: 5-(1-Fluoro-3-hydroxy-8-(isopentyl(methyl)amino)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0282]

[0283] To a solution of Example 25 (15 mg, 31 μmol, 1 eq) in MeOH (3 mL) was added formaldehyde (115 mg, 1.5 mmol, 105 uL, 40% purity, 50 eq) and Pd / C (10 mg, 10% purity), followed by H 2(15 psi) was purged and stirred at 25 °C for 1 hour. The reaction mixture was then filtered and concentrated under reduced pressure to give the crude material. The crude material was then purified by preparative HPLC to give Example 28 (2.0 mg, 4.6 μmol, 15% yield, 95%) as a white solid. LCMS (ESI-): m / z=412.2 (MH) - . 1 H NMR (400MHz, CD 3 OD)δ6.58(s,1H),4.27(s,1H),3.38(br s,1H),3.28-3.11(m,3H),2.99-2.63(m,6H),2.33-1.95(m,3H),1.79-1.40(m,4H),1.00(d,J=6.4Hz,6H).

[0284] Example 29: 5-(1-Fluoro-3-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0285]

[0286] Step 1: General procedure for compound 29-2

[0287] To a solution of 29-1 (3 g, 19.4 mmol, 1 eq.) in THF (30 mL) was added (E)-4-diethoxyphosphorylbut-2-enoic acid methyl ester (6.9 g, 29 mmol, 1.5 eq.) and NaH (1.17 g, 29 mmol, 60% purity, 1.5 eq.), followed by N 2 It was cooled to 0°C under reduced pressure. It was then heated to 80°C and stirred for 16 hours. The resulting reaction mixture was washed with saturated NH 4 Cl (aqueous solution) (50 mL) was quenched, followed by extraction with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% ethanol / ethyl acetate = 100 / 1 to 5 / 1) to give 29-2 (10.5 g, 44 mmol, 25% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3)δ7.43(ddd,J=1.6,8.7,15.3Hz,1H),6.86-6.75(m,4H),6.58(td,J=2.2,10.4Hz,1H),6.03(d,J=15.3Hz,1H),3.83(s,3H),3.78(s,3H).

[0288] Step 2: General procedure for compound 29-3

[0289] To a solution of 29-2 (3.5 g, 14.8 mmol, 1 eq.) in THF (80 mL) was added Pd / C (1.5 g, 10% purity), followed by HCl. 2 The mixture was purged with 15 psi and stirred at 25° C. for 16 hours. The reaction mixture was then filtered and concentrated under reduced pressure to give 29-3 (10.8 g, crude) as a colorless oil. 1 H NMR (400 MHz, CDCl 3 )δ6.55-6.39(m,3H),3.79(s,3H),3.68(s,3H),2.59(t,J=7.1Hz,2H),2.37-2.31(m,2H),1.70-1.61(m,4H).

[0290] Step 3: General procedure for compound 29-4

[0291] At -5 °C, 29-3 (3.6 g, 14.9 mmol, 1 eq.) was added to H 2 LiOH-HCO(2) was added to a solution of 2H2O(9 mL), MeOH(18 mL) and THF(18 mL). 2 O (855 mg, 20.3 mmol, 1.36 equiv). The reaction mixture was then warmed to 25 °C and stirred for 12 h. The resulting reaction mixture was concentrated under reduced pressure and then resuspended in H 2 O (50 mL) and extracted with ethyl acetate (50 mL). The aqueous layer was adjusted to pH = 2 to 3 with 2N HCl (aqueous solution), then extracted with ethyl acetate (50 mL×3), and then 2 SO 4 Drying, subsequent filtration and concentration under reduced pressure afforded 29-4 (10.2 g, crude) as an orange solid. 1 H NMR (400 MHz, CDCl 3 )δ6.59-6.39(m,3H),3.79(s,3H),2.60(br t,J=6.8Hz,2H),2.44-2.33(m,2H),1.68(td,J=3.5,7.0Hz,4H).

[0292] Step 4: General procedure for compound 29-5

[0293] PPA (3.4 g) was added to a solution of 29-4 (3.4 g, 15.03 mmol, 1 eq.) in chlorobenzene (35 mL), which was then heated to 80 °C and stirred for 12 hours. The resulting reaction mixture was concentrated under reduced pressure, then resuspended in ethyl acetate (70 mL) and washed with 1N NaOH (aqueous solution) (30 mL), followed by brine (30 mL). The combined organic layers were purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (50% by weight, 4% by weight, petroleum ether / ethyl acetate = 100 / 1 to 5 / 1) to give 29-5 (5.5 g, 26.4 mmol, 58% yield) as a yellow oil.

[0294] 1 H NMR (400 MHz, CDCl 3 )δ6.62-6.40(m,2H),3.85-3.74(m,3H),2.81(t,J=6.3Hz,1H),2.73(br t,J=6.2Hz,1H),2.68-2.59(m,2H),1.89-1.75(m,4H).

[0295] Step 5: General procedure for compound 29-6

[0296] In N 2 To a solution of 29-5 (1.1 g, 5.28 mmol, 1 eq) in TFA (11 mL) was added triethylsilane (3.07 g, 26.4 mmol, 4.2 mL, 5 eq) dropwise under 4% CO. The reaction mixture was then heated to 60 °C and stirred for 12 h. To the resulting reaction mixture was added H 2 O (25 mL), and then extracted with ethyl acetate (25 mL×3). The combined organic layers were washed with brine (30 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 , petroleum ether / ethyl acetate=1 / 0 to 99 / 1) to give 29-6 (2.7 g, crude) as a brown oil. 1 HNMR (400MHz, CDCl 3 )δ6.58-6.33(m,2H),3.77(s,3H),2.85-2.68(m,4H),1.89-1.76(m,2H),1.70-1.57(m,4H).

[0297] Step 6: General procedure for compound 29-7

[0298] At 0 °C, 29-6 (0.9 g, 4.63 mmol, 1 eq.) was added to CH 2 Cl 2 BBr was added dropwise to the solution in 1% HCl (30 mL). 3 (5.8 g, 23.1 mmol, 2.23 mL, 5 eq.) and in N 2 The resulting reaction mixture was poured into 1M HCl (50 mL) and stirred for 5 minutes, followed by addition of CH 2 Cl 2 The combined organic layers were washed with brine (30 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% ethanol, 1.2% ethanol, 0.1% ethanol, 0.2% ethanol, 0.3% ethanol, 0.4% ethanol, 0.6% ethanol, 0.8% ethanol, 0.9% ethanol, 0.1% ethanol, 0.2% ethanol, 0.3% ethanol, 0.6% ethanol, 1 HNMR (400MHz, CDCl 3 )δ6.48-6.30(m,2H),4.63(s,1H),2.85-2.62(m,4H),1.91-1.77(m,2H),1.61(tdd,J=5.6,10.9,16.6Hz,4H).

[0299] Step 7: General procedure for compound 29-8

[0300] To a solution of 29-8 (0.44 g, 2.4 mmol, 1 eq) in THF (5 mL) at 0 ° C., 1-(chloromethoxy)-2-methoxy-ethane (456 mg, 3.6 mmol, 418 μL, 1.5 eq) and NaH (195 mg, 4.8 mmol, 60% purity, 2 eq) were added. The reaction mixture was then warmed to 25 ° C. and stirred for 12 hours. The resulting reaction mixture was washed with saturated NH 4 Cl (aqueous solution) (20 mL) was quenched, followed by extraction with ethyl acetate (15 mL×3). The combined organic layers were washed with brine (30 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave the crude material. 2 The crude material was purified by HPLC-MS / MS (HPLC-MS / MS): 5:1, petroleum ether / ethyl acetate = 5:1, Rf = 0.52) to give 29-8 (2.35 g, 8.7 mmol, 71% yield) as a brown oil. 1HNMR (400MHz, CDCl 3 )δ6.68-6.57(m,2H),5.22(s,2H),3.82(dd,J=3.9,5.4Hz,2H),3.57(dd,J=3.8,5.5Hz,2H),3.39(s,3H),2.76(br dd,J=3.4,7.2Hz,4H),1.87-1.78(m,2H),1.61(dt,J=5.1,10.1Hz,4H).

[0301] Step 8: General procedure for compound 29-9

[0302] To a solution of 2,2,6,6-tetramethylpiperidine (494 mg, 3.5 mmol, 594 μL, 2 eq.) in THF (5 mL) was added 2.5 M n-BuLi (1.40 mL, 2 eq.) dropwise at 0 °C and stirred at N 2 The reaction mixture was then cooled to -78 °C and a solution of 29-8 (470 mg, 1.75 mmol, 1 eq) in THF (5 mL) and N,N,N',N'-tetramethylethane-1,2-diamine (305 mg, 2.63 mmol, 396 μL, 1.5 eq) was added, followed by stirring for another 2 hours. I was then added to the reaction mixture 2 (1.11 g, 4.38 mmol, 882 μL, 2.5 equiv) in THF (5 mL) and stirred for another 10 min. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 20 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (15 mL×3). The combined organic layer was washed with water (20 mL) and brine (20 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave the crude material. 2 The crude material was purified by HPLC-MS / MS (HPLC-MS / MS): 50444-0.7544 (0.2547 W / mL, petroleum ether / ethyl acetate=10:1, Rf=0.45) to give 29-9 (3 g, 7.61 mmol, 86% yield) as a brown oil. 1 H NMR (400 MHz, CDCl 3)δ6.73(s,1H),5.32(s,2H),3.94-3.81(m,2H),3.65-3.53(m,2H),3.39(s,3H),2.89-2.69(m,4H),1.88-1.77(m,2H),1.67-1.57(m,4H).

[0303] Step 9: General procedure for compounds 29-10

[0304] To a solution of 29-9 (1.5 g, 3.80 mmol, 1 eq) in 1,4-dioxane (15 mL) were added tert-butyl 2-aminoacetate (748 mg, 5.7 mmol, 1.5 eq) and Cs 2 CO 3 (2.48 g, 7.61 mmol, 2 eq.), then degassed in vacuo and heated with N 2 The mixture was purged 3 times. Dicyclohexyl-[3,6-dimethoxy-2-(2,4,6-triisopropyl-phenyl)phenyl]phosphane (204 mg, 380 μmol, 0.1 eq.) and [2-(2-aminophenyl)phenyl]-methylsulfonyl-oxy-palladium, dicyclohexyl-[3,6-dimethoxy-2-(2,4,6-triisopropylphenyl)phenyl]phosphane (344 mg, 380 μmol, 0.1 eq.) were then added and the mixture was degassed again under vacuum and heated to 40 ℃ for 2 hours. 2 The reaction mixture was then heated to 90 °C and stirred for 16 h. H 2 O (30 mL), and then extracted with ethyl acetate (25 mL×3). The combined organic layers were washed with brine (30 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% ethanol, 0.24mmol, 3% CO, 0.5% CO, 0.2% MgSO4), to give 29-10 (2.1 g, 5.28 mmol, 69% yield) as a brown oil. 1 HNMR (400MHz, CDCl 3 )δ6.69(s,1H),5.26(s,2H),3.95(d,J=1.9Hz,2H),3.86(dd,J=3.8,5.5Hz,2H),3.61-3.55 (m,2H),3.39(s,3H),2.78-2.65(m,4H),1.83-1.74(m,2H),1.64-1.55(m,4H),1.45(s,9H).

[0305] Step 10: General procedure for compounds 29-11

[0306] To N-(oxymethylene)sulfamoyl chloride (1.44 g, 10.19 mmol, 884 μL, 4.5 equiv.) was added to CH 2 Cl 2 Prop-2-en-1-ol (591 mg, 10.19 mmol, 692 μL, 4.5 eq.) was added to a solution in 4% paraformaldehyde (15 mL) and the mixture was stirred at 0 °C under N 2 Then, 29-10 (0.9 g, 2.26 mmol, 1 eq.) and N,N-diethylethylamine (458 mg, 4.53 mmol, 630 μL, 2 eq.) were added to the mixture in CH 2 Cl 2 (10 mL) and stirred for another 0.5 h. To the resulting reaction mixture was added H 2 O (30 mL), followed by CH 2 Cl 2 The combined organic layers were washed with brine (30 mL) and purified by Na 2 SO 4 Drying, subsequent filtration and concentration under reduced pressure afforded 29-11 (1.5 g, crude) as a brown oil. 1 H NMR (400 MHz, CDCl 3 )δ6.80(s,1H),6.04-5.82(m,1H),5.38(dd,J=1.4,17.1Hz,1H),5.30-5.25(m,2H),4.68(d,J=5.8Hz,2H),4.23(d,J=17.8Hz,1H),3.86 (td,J=3.7,5.7Hz,2H),3.55(dt,J=3.5,5.7Hz,2H),3.35(s,3H),2.84-2.70(m,4H),1.86-1.78(m,2H),1.68-1.55(m,4H),1.44(s,9H).

[0307] Step 11: General procedure for compounds 29-12

[0308] To a solution of 29-11 (0.5 g, 891 μmol, 1 eq) in MeOH (5 mL) were added NaOMe (481 mg, 2.68 mmol, 30% purity, 3 eq) and Pd(PPh 3 ) 4 (30 mg, 26 μmol, 0.03 eq.), which was then heated to 60 °C and stirred under N 2The resulting suspension was quenched by adding 1M HCl (30 mL) and then extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (20 mL) and purified by Na 2 SO 4 Drying, subsequent filtration and concentration under reduced pressure afforded 29-12 (1.1 g, crude) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ6.82(s,1H),5.31(s,2H),4.42(s,2H),3.86(dd,J=3.6,5.4Hz,2H),3.62-3 .53(m,2H),3.47-3.32(m,3H),2.84-2.72(m,4H),1.88-1.78(m,2H),1.64(br dd,J=5.4,11.0Hz,4H).

[0309] Step 12: General procedure for compound Example 29

[0310] A solution of 29-12 (500 mg, 1.24 mmol, 1 eq.) in 4M HCl / dioxane (20 mL, 64 eq.) was stirred at 25 °C for 30 min. The reaction mixture was then concentrated under reduced pressure to give a crude material. The crude material was then purified by preparative HPLC to give Example 29 (212 mg, 653 μmol, 26% yield). LCMS (ESI-): m / z=313.1 (MH) - . 1 H NMR (400 MHz, DMSO-d 6 )δ6.54(s,1H),4.38(s,2H),2.76-2.58(m,4H),1.76(br d,J=4.1Hz,2H),1.61-1.46(m,4H).

[0311] Example 30: 5-(6-Fluoro-8-hydroxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine -7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0312]

[0313]

[0314] Step 1: General procedure for compound 30-2

[0315] 30-1 (200 g, 858 mmol, 1 eq.) was added to CH 2 Cl 2Add (COCl) to the solution (1L) 2 (163.4 g, 1.29 mol, 112 mL, 1.5 eq.) and DMF (12.5 g, 171.6 mmol, 13.2 mL, 0.2 eq.) and stirred at 0 °C under N 2 The mixture was stirred at 40 °C for 1 hour. The reaction mixture was then concentrated under reduced pressure to obtain 30-2 (220 g, crude material) as a brown oil. LCMS (ESI+): m / z=245.1 / 247.1 (M-OCl+MeOH) + .

[0316] Step 2: General procedure for compound 30-3

[0317] At 0°C, AlCl 3 (349.9 g, 2.62 mol, 143 mL, 3 eq.) in CH 2 Cl 2 (1.5 L) was added to CH 2 Cl 2 30-2 (220 g, 874 mmol, 1 eq.) in (500 mL). The reaction mixture was then stirred for 1 hour, followed by the addition of ethylene, followed by further stirring for 2 hours. H 2 O(1L), followed by CH 2 Cl 2 The combined organic layers were washed with brine (500 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC (5% by weight, 4% by weight, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to give 30-3 (130 g, 534.82 mmol, 61% yield). 1 H NMR (CDCl 3 )δ7.21(s,1H),7.18-7.12(m,1H),3.51(s,2H),3.08(t,J=6.8Hz,2H),2.63-2.55(m,2H).

[0318] Step 3: General procedure for compound 30-4

[0319] To a solution of 30-3 (130 g, 534 mmol, 1 eq.) in MeOH (1.3 L) was added NH 2OH-HCl (55.7 g, 802 mmol, 1.5 eq.) and NaOAc (87.7 g, 1.07 mol, 2 eq.) were added and stirred at 25 °C for 1.5 h. The resulting reaction mixture was concentrated under reduced pressure to remove MeOH. H 2 O (300 mL), and then extracted with ethyl acetate (150 mL×3). The combined organic layers were washed with brine (300 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded the crude material. The crude material was triturated with petroleum ether to afford 30-4 (100 g, 387 mmol, 72% yield) as a light solid. 1 H NMR (CDCl 3 )δ9.02-8.39 (m, 1H), 7.16 (s, 1H), 7.14-7.09 (m, 2H), 3.74 (s, 2H), 3.55-3.48 (m, 1H), 2.95-2.84 (m, 3H), 2.79-2.71 (m, 1H), 2.60-2.52 (m, 2H). Step 4: General procedure for compound 30-5

[0320] At 0°C, in N 2 30-4 (6 g, 23.25 mmol, 1 eq.) was added to CH 2 Cl 2 1 M DIBALH (116 mL, 5 eq.) was added dropwise to a solution of 4% paraformaldehyde (60 mL). The reaction mixture was then stirred at 25 °C for 2 h. The reaction mixture was then cooled to 0 °C and added to H 2 NaF (9.7 g, 232 mmol, 9.7 mL, 10 equiv) in 20 mL of DMF. The reaction mixture was then warmed to 25 °C and stirred for another 2 h. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 100 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (100 mL×2). The combined organic layer was washed with water (100 mL) and brine (100 mL), and then washed with Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded the crude material. The crude material was then purified by HPLC to afford 30-5 (1 g, 4.10 mmol, 17% yield) as a white solid. 1 H NMR (CD 3OD)δ7.31-7.27(m,2H),3.33-3.29(m,4H),3.22-3.17(m,4H).

[0321] Step 5: General procedure for compound 30-6

[0322] 30-5 (0.5 g, 2.05 mmol, 1 eq.) was added to CH 2 Cl 2 Boc 2 O (894 mg, 4.1 mmol, 941, 2 eq.) and DMAP (25.02 mg, 204.83 μmol, 0.1 eq.) were added, followed by stirring at 25 °C for 12 h. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 10 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (10 mL) and brine (10 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (0.7 g, 2.03 mmol, 99% yield) to afford 30-6 as a yellow oil. 1 H NMR (CDCl 3 )δ7.12-7.07 (m, 2H), 3.59-3.50 (m, 4H), 2.94-2.86 (m, 4H), 1.48 (s, 9H). Step 6: General procedure for compound 30-8

[0323] To a solution of 30-6 (0.7 g, 2.03 mmol, 1 eq) in 1,4-dioxane (10 mL) were added 30-7 (1.03 g, 4.07 mmol, 2 eq), Pd(dppf)Cl 2 (148 mg, 203 μmol, 0.1 eq) and KOAc (798 mg, 8.1 mmol, 4 eq), followed by N 2 It was heated to 90 °C for 2 h. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3(aqueous solution) (1:1, 10 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (10 mL) and brine (10 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 , petroleum ether / ethyl acetate=1 / 0 to 0 / 1) to give 30-8 (1.3 g, crude) as a yellow solid. 1 H NMR (CDCl 3 )δ7.34-7.30(m,2H),3.57-3.51(m,4H),2.99-2.90(m,4H),1.33(s,9H),1.26(s,12H).

[0324] Step 7: General procedure for compound 30-9

[0325] To a solution of 30-8 (1.2 g, 3.07 mmol, 1 eq.) in acetone (20 mL) was added H 2 Potassium monopersulfate (3.77 g, 6.13 mmol, 2 eq.) in 2% CO (20 mL) was added, followed by stirring at 0° C. for 0.5 h. H 2 O (50 mL), and then extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC (solidified water, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to give 30-9 as a colorless oil. 1 H NMR (CDCl 3 )δ6.49-6.43(m,2H),3.58-3.50(m,4H),2.89-2.82(m,4H),1.49(s,9H).

[0326] Step 8: General procedure for compound 30-10

[0327] To a solution of 30-9 (0.7 g, 2.49 mmol, 1 eq.) in THF (10 mL) was added NaH (199 mg, 4.9 mmol, 60% purity, 2 eq.), followed by heating at 0 °C under N 2MEMCl (464 mg, 3.73 mmol, 426 μL, 1.5 eq.) was then added to the reaction mixture, which was then warmed to 25°C and stirred for another 12 hours. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 20 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (20 mL) and brine (30 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (5% CO, 4% CO, 0.1% NH 2 0 4 mmol, 0.2% CO 2 0 4 0 0 0 0 ) to afford 30-10 (0.7 g, 1.89 mmol, 76% yield) as a yellow solid. 1 H NMR (CDCl 3 )δ6.69-6.61 (m, 2H), 5.23 (s, 2H), 3.83-3.80 (m, 2H), 3.59-3.49 (m, 6H), 3.39 (s, 3H), 2.87 (br d, J=4.8 Hz, 4H), 1.49 (s, 9H). Step 9: General procedure for compound 30-11

[0328] To a solution of 2,2,6,6-tetramethylpiperidine (497 mg, 3.5 mmol, 597 μL, 2 eq) in THF (6 mL) at 0°C was added 2.5 M n-BuLi (1.41 mL, 2 eq) dropwise, followed by N 2 The reaction mixture was then cooled to -78 °C and then 30-10 (0.65 g, 1.76 mmol, 1 eq) in THF (3 mL) was added, followed by tetramethylethylenediamine (306 mg, 2.64 mmol, 398 μL, 1.5 eq) and stirred for another 2 hours. Then 1 in THF (1.5 mL) was added 2 (1.12 g, 4.4 mmol, 886 μL, 2.5 equiv.) The reaction mixture was then warmed to 25°C and stirred for another hour. The resulting suspension was washed with saturated NH 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3(aqueous solution) (1:1, 10 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (20 mL) and brine (20 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded the crude material. The crude material was then purified by column chromatography to afford 30-11 (0.71 g, 1.43 mmol, 81% yield) as a yellow solid. 1 H NMR (CDCl 3 )δ6.73(s,1H),5.32(s,2H),3.90-3.84(m,2H),3.59-3.49(m,6H),3.38(s,3H),2.96-2.85(m,4H),1.48(s,9H).

[0329] Step 10: General procedure for compounds 30-13

[0330] To a solution of 30-11 (0.65 g, 1.31 mmol, 1 eq.) in 1,4-dioxane (7 mL) were added 30-12 (258 mg, 1.97 mmol, 1.5 eq.), Cs 2 CO 3 (1.28 g, 3.94 mmol, 3 eq.), XPhos (125.12 mg, 262.46 μmol, 0.2 eq.), and BrettPhos Pd G 3 (118 mg, 131 μmol, 0.1 eq.), followed by N 2 It was heated to 90 °C for 48 h. 4 Cl (aqueous solution) and 1M Na 2 S 2 O 3 (aqueous solution) (1:1, 15 mL) was quenched and stirred at 25 ° C for 5 minutes. The resulting reaction mixture was then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with water (10 mL) and brine (10 mL), and then purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure gave a crude material. 2 The crude material was purified by HPLC-MS / MS (0.50447 / 0.00444, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to afford 30-13 (0.5 g, 1.0 mmol, 76% yield) as a yellow oil. 1 H NMR (CDCl 3)δ6.70(br s,1H),5.26(br s,2H),3.95(br s,2H),3.91-3.80(m,2H),3.64-3.48(m,6H),3.47-3.33(m,3H),3.07-2.64(m,4H),1.67-1.41(m,18H).

[0331] Step 11: General procedure for compounds 30-14

[0332] To N-(oxymethylene)sulfamoyl chloride (191 mg, 1.35 mmol, 117 μL, 1.5 equiv) was added CHCl. 2 Cl 2 To a solution in 4% paraformaldehyde (5 mL) was added prop-2-en-1-ol (157 mg, 2.7 mmol, 184 μL, 3 eq) and stirred at 0°C for 0.5 h. The reaction mixture was then warmed to 25°C and then added to CH 2 Cl 2 30-13 (0.45 g, 902 μmol, 1 eq.) and diisopropylethylamine (116 mg, 902 μmol, 157 μL, 1 eq.) were added to 1% ethanol (2 mL) and stirred for another hour. H 2 O (5 mL), then CH 2 Cl 2 The combined organic layers were washed with brine (10 mL) and purified by Na 2 SO 4 Drying, subsequent filtration and concentration under reduced pressure afforded 30-14 (0.5 g, crude) as a yellow oil.

[0333] Step 12: General procedure for compounds 30-15

[0334] To a solution of 30-14 (0.3 g, 453 μmol, 1 eq) in MeOH (3 mL) were added NaOMe (408 mg, 2.27 mmol, 30% purity, 5 eq) and Pd(PPh 3 ) 4 (52 mg, 45 μmol, 0.1 eq.), followed by N 2 It was heated to 60 °C for 1 hour. Then H 2 O (5 mL), followed by CH 2 Cl 2 The combined organic layers were washed with brine (10 mL) and purified by Na 2 SO 4 Drying, followed by filtration and concentration under reduced pressure afforded 30-15. 1HNMR (CD 3 OD)δ6.90(s,1H),5.29(s,2H),4.24(s,2H),3.88-3.81(m,2H),3.62-3.50(m,6H),3.34-3.32(m,3H),3.00-2.87(m,4H),1.46(s,9H).

[0335] Step 13: General procedure for compound Example 30

[0336] A solution of 30-15 (0.15 g, 297 μmol, 1 eq.) in 4M HCl / EtOAc (5 mL) was stirred at 25°C for 1 hour. The resulting reaction mixture was filtered and concentrated under reduced pressure to give the crude material. The crude material was purified by HPLC to give Example 30 (0.1 g). LCMS (ESI-): m / z=314.0 (MH) - . 1 H NMR (D 2 O)δ6.64(s,1H),4.31(s,2H),3.26(brt,J=9.4Hz,4H),3.09-3.02(m,4H).

[0337] Example 31: 5-(6-Fluoro-8-hydroxy-3-(4-methylpentyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine -7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0338]

[0339] To a solution of Example 30 (0.15 g, 475 μmol, 1 eq.) in acetonitrile (5 mL) were added 30-16 (71 mg, 713 μmol, 1.5 eq.) and diisopropylethylamine (61 mg, 475 μmol, 82 μL, 1 eq.) and stirred at 25 °C for 1 hour. Then NaBH 3 CN (119 mg, 1.9 mmol, 4 eq) and stirred for another 12 h.

[0340] The resulting reaction mixture was filtered and concentrated under reduced pressure to give a crude material. The crude material was purified by HPLC to give Example 31 (22 mg). LCMS (ESI+): m / z=400.3 (M+H) + . 1 H NMR (D 2O)δ6.68(s,1H),4.33(s,2H),3.37(brs,4H),3.19-3.04(m,6H),1.78-1 .66(m,2H),1.61-1.50(m,1H),1.27-1.15(m,2H),0.85(d,J=6.6Hz,6H).

[0341] Example 33: 5-(6-Fluoro-8-hydroxy-3-(4-methylpentyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine -7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide

[0342]

[0343] Example 33 was synthesized as described in any of the above Examples. LCMS (ESI-): m / z=384.1 (MH) - . 1 H NMR (400 MHz, DMSO-d 6 )δ8.99(s,1H),6.59(s,1H),3.91(s,2H),2.94-2.97(m,2H),2.64-2.66(m,6H),2 .32(m,1H),1.86-1.88(m,2H),1.50-1.52(m,3H),1.22-1.23(m,3H),1.01(m,2H).

[0344] Example A: Enzyme Assay for Determining the Potency of PTPN2 Inhibitors

[0345] Unlabeled full-length human PTPN2 (TC45) (1-387) protein was used in an in vitro enzyme assay to determine compound activity. PTPN2 was produced as a GST-TEV fusion in E. coli and GST was removed by TEV digestion, followed by additional purification to produce full-length PTPN2 (SEQ ID 1). The PTPN2 enzyme was diluted to a final concentration of 0.5 nM in assay buffer (50 mM HEPES pH 7.5, 0.2 mM EDTA, 1 mM DTT, 0.02% Brij-35, 0.02% BSA) and added to a black 384-well non-binding plate (Greiner, 781900). Compounds were then added using a Tecan D300e dispenser. After incubation at room temperature for 10 minutes, DiFMUP substrate (ThermoFisher, D22065) was added to a final concentration of 100 μM. The plates were transferred to a SpectraMax plate reader (Molecular Devices) and fluorescence intensity (excitation 358, emission 455) was measured after 30 minutes of incubation at room temperature. Each plate included a 100% inhibition control (no enzyme) and a 0% inhibition control (DMSO), from which the % inhibition of the test compound was calculated. IC was determined from the % inhibition data using a four-parameter curve fit. 50 value.

[0346] Example B: B16F10 cell growth inhibition assay

[0347] Compound activity was determined using an interferon gamma (IFNγ)-induced cell growth inhibition assay on an Agilent xCELLigence real-time cell analysis platform (RTCA) using a murine B16F10 melanoma cell line. Prior to taking initial impedance (scan) measurements, RTCA E-Plate View 96 plates (Agilent, 300601010) were pre-equilibrated with 50 μL of assay medium (DMEM + 10% FBS, Gibco 10566-024, Gibco 10082-147) at 37°C in a humidified incubator. B16F10 cells cultured in assay medium were dissociated with TrypLE Express (Gibco 12605-010) at 37°C for five minutes, diluted in 3 volumes of assay buffer, centrifuged at 500xg for 5 minutes at room temperature, then diluted to 7,700 cells / ml in assay medium, 130 μL / well (1,000 cells / well) were seeded in the inner 60 wells of the assay plate, and 150 μL of assay medium was added to the outer wells of the plate. The cells were incubated at room temperature for 20 minutes to allow the cells to settle, then placed in the xCELLigence reader and incubated overnight at 37°C, with wells scanned every 15 minutes. After 24 hours, well readings were paused, the plate was removed from the incubator and compounds were added using a Tecan D300e dispenser. All wells were normalized to a final concentration of 0.5% DMSO. After incubation at 37°C for 30 minutes, recombinant mouse IFNγ (R&D Systems) was added in assay medium. TM 485MI100) was diluted to 10 ng / mL and 20 μL was added to the assay wells (1 ng / mL final concentration). The assay plate was placed in the xCELLigence reader and scanned every 15 minutes. After 48 hours, the well readings were normalized to the time point immediately prior to compound addition and the area under the growth curve (AUC) was calculated and exported by RTCA software. A four-parameter curve fit was used to determine the compound IC using the % inhibition of each compound concentration. 50 Values ​​were calculated using DMSO vehicle and IFNγ treatment as baseline (0% inhibition) and positive control PTPN2 inhibitor and IFNγ treatment as 100% inhibition.

[0348] The data from Example A and Example B are shown in Table 3.

[0349] Table 3

[0350]

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: in: Ring A is a 7- to 15-membered cycloalkyl group or a 7- to 15-membered heterocycloalkyl group containing 1 to 4 heteroatoms selected from O, S and N; Each R 1 are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally replaced by one or more R 1a replace; or two R on the same atom 1 Together they form an oxo group; Each R 1a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R; or two R on the same atom 1a Together they form an oxo group; n is 0 to 6; X is CR X or N; R X Hydrogen, deuterium, halogen, -CN, -NO2, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Y is CR Y or N; R Y Hydrogen, deuterium, halogen, -CN, -NO2, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Z is CR Z or N; R Z Hydrogen, deuterium, halogen, -CN, -NO2, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; W is CR W or N; R W Hydrogen, deuterium, halogen, -CN, -NO2, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl (cycloalkyl), C1-C6 alkyl (heterocycloalkyl), C1-C6 alkyl (aryl) or C1-C6 alkyl (heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R; Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), C1-C6 alkyl(aryl) or C1-C6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R; Each R c and R d is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), C1-C6 alkyl(aryl) or C1-C6 alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted with one or more R; or R c and R d together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; and Each R is independently deuterium, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(=O)2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC C1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; Or two R on the same atom together form an oxo group.

2. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein ring A is a 7- to 8-membered cycloalkyl group.

3. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein ring A is a 7-membered cycloalkyl group.

4. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein Ring A is a 7- to 8-membered heterocycloalkyl group containing 1 to 4 heteroatoms selected from O, S and N. 5 . The compound according to claim 1 , or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein Ring A is a 7-membered heterocycloalkyl group containing 1 to 4 heteroatoms selected from O, S and N.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein X is N.

7. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein X is CR X .

8. A compound according to any one of claims 1 to 5 or 7, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R X It is a halogen.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein Y is N.

10. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein Y is CR Y .

11. A compound according to any one of claims 1 to 8 or 10, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R Y It is -OH.

12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein Z is N.

13. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein Z is CR Z .

14. A compound according to any one of claims 1 to 11 or 13, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R Z For hydrogen.

15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein W is N.

16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally replaced by one or more R 1a In some embodiments of the compound of Formula (I), each R 1 are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently and optionally replaced by one or more R 1a replace.

17. A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 are independently -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 aminoalkyl or heterocycloalkyl; wherein each alkyl and heterocycloalkyl is independently and optionally replaced by one or more R 1a replace.

18. A compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 are independently -OH, -NR c R d , C1-C6 alkyl, C1-C6 aminoalkyl or heterocycloalkyl; wherein each alkyl and heterocycloalkyl is independently and optionally substituted by one or more R 1a replace.

19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 Independently -NR c R d or optionally one or more R 1a Substituted C1-C6 alkyl.

20. The compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 Independently -NR c R d .

21. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 are independently optionally replaced by one or more R 1a Substituted C1-C6 alkyl.

22. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 1 are independently C1-C6 alkyl.

23. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein n is 0 or 1.

24. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein n is 1 or 2.

25. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein n is 1.

26. The compound of claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound is selected from the compounds of Table 1 or Table 2.

27. A pharmaceutical composition comprising a compound according to any one of claims 1 to 26 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and a pharmaceutically acceptable excipient.

28. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as described in any one of claims 1 to 26, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

29. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 27.

30. The method of claim 28 or 29, further comprising administering an additional therapeutic agent.

31. The method of claim 30, wherein the additional therapeutic agent is an immunotherapeutic agent.

32. The method of claim 31, wherein the immunotherapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

33. A method of treating type 2 diabetes in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as described in any one of claims 1 to 26, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

34. A method of treating type 2 diabetes in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 27.

35. A method of treating and / or controlling obesity in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as described in any one of claims 1 to 26, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

36. A method of treating and / or managing obesity in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 27.

37. A method of treating a metabolic disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as described in any one of claims 1 to 26, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

38. A method of treating a metabolic disease in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 27.